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Summary
Despite having revolutionized the treatment of psychiatric illnesses, 
atypical antipsychotic agents raise an increasing medical concern 
regarding their association with prominent body weight gain and 
metabolic abnormalities resulting from chronic treatment. As a 
consequence, the use of atypical antipsychotic medication has been 
linked to a substantial increase in the development of obesity, type 2 
diabetes and cardiovascular diseases in patients undergoing therapy.
In this study, the primary aim was to develop a mouse model of atypical 
antipsychotic-induced body weight gain and adiposity. Moreover, the 
chosen antipsychotic agents, clozapine and olanzapine, were 
investigated in a fibroblast-like cell line model (7-F2) and in primary 
bone marrow cells, in order to test a possible direct contribution by 
these agents in causing adipogenesis and altered lipid metabolism at 
the cellular level in peripheral tissues.
It was found that the ability to produce a reliable and robust mouse 
model, capable of mimicking the clinical situation was obstructed by 
variability and inconsistency of the experimental outcomes. This 
prompts the suggestion that caution should be exercised in the 
interpretation of results from previous models and also, to question their 
predictive validity.
Furthermore, although a morphological study on 7-F2 cells showed that 
clozapine and olanzapine do not enhance the differentiation of 
fibroblastic cells into adipocytes, mRNA over-expression of genes 
involved in adipocyte formation and metabolism suggest that these 
antipsychotics incite de novo formation of fat cells in the bone marrow.
Overall, although the results are of a preliminary nature, they 
emphasize the need for in-depth examination of any possibility that 
clozapine or olanzapine might directly trigger an increase in adipocyte 
numbers (hyperplasia) or alter adipocyte size (hypertrophy).
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Chapter 1
Chapter 1 
General Introduction
1
Chapter 1
1. Schizophrenia and antipsychotic drugs
1.1 The nature of schizophrenia
Schizophrenia (skizo-to split’ and phrenia-mind’) can be defined as a 
neuropsychiatric disorder characterized by dysfunctions in the 
perception of reality. It is estimated that 1% of the world population 
suffer from schizophrenia with the peak onset of the disorder between 
10 and 25 years old for males and between 25 and 35 for women (Rajji 
et al., 2009).
1.1.1 Symptoms
Schizophrenia symptoms may vary from patient to patient and are often 
classified as positive and/or negative. Positive symptoms reflect a
2
Chapter 1
pattern of behavior that is not normally present in a healthy subject (i.e 
hallucinations, delusions, bizarre behavior and thoughts) while the 
negative symptoms define diminished functions in comparison to a 
normal subject (i.e asociality, anhedonia, avolition) (Fuller and Schultz, 
2003). In addition, cognitive symptoms such as memory deficit and 
attention can be present (Fuller and Schultz, 2003).
1.1.2 Diagnosis
The two most widely used sets of criteria to diagnose schizophrenia are 
described in the Diagnostic and Statistical Manual (DSM-IV) of the 
American Psychiatry Society and the International Classification of 
Diseases (ICD-10) of the World Health Organization.
1.1.3 Causes of schizophrenia
Despite years of investigation, the origin of schizophrenia remains 
uncertain. Nevertheless several risk factors were identified:
3
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Season of birth
Some studies showed that the late onset of schizophrenia is linked to a 
slight excess of births in winter and spring in the northern hemisphere, 
and a slight decrease over summer and autumn (Mortensen et al., 
1999; Torrey et al., 1997).
Prenatal and birth complications
Late development of schizophrenia seems to be related to prenatal and 
birth complication as several studies and meta-analyses have 
confirmed. Among them: prenatal exposure to infections (Brown, 2006), 
complications of pregnancy, abnormal fetal growth and development, 
complications of delivery (Cannon et al., 2002).
Environment
Being born in an urban environment has been repeatedly found to 
increase the risk of developing schizophrenia (Van Os et al., 2005). 
Migration (i.e. foreign birth and background) (Cantor-Graae et al., 2003) 
and poverty (Mueser and McGurk, 2004) also appear to have their 
influence.
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Genetics
It has long been recognized that schizophrenia is a disorder with a 
hereditary component.
Both familiar and twin studies have demonstrated the existence of 
genetic factors responsible for the onset of schizophrenia (O’Donovan 
et al., 2003), although the identification of specific genes or any 
involvement of genetic variations is still uncertain.
1.1.4 The neuropathology of schizophrenia
Since the introduction of modern imaging technologies such as PET 
and MRI, researchers have uncovered a number of small anatomical 
abnormalities in the brain structures of individuals affected by 
schizophrenia. Most of these changes appear to involve the temporal 
and frontal lobe (Lawrie and Abukmeil, 1998). Moreover, differences in 
brain size and volume have been found, total volume being slightly 
reduced and ventricular volume being enlarged (Steen et al., 2006).
5
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1.1.5 The neurochemistry of schizophrenia
The dopamine and glutamate hypotheses are the two classical theories 
hypothesized to explain the symptoms of schizophrenia.
Dopamine hypothesis. Since early in the 1960s, a dysregulation of 
dopamine transmission has been suggested as an underlying 
aetiological factor in schizophrenia (Carlsson and Linqvist, 1963) and 
later on, this was followed by the observation that antipsychotic drugs 
were effective against the positive symptoms of schizophrenia by 
blocking dopaminergic D2 receptors (Creese et al., 1976). Additionally, 
psychotropic drugs acting as D2 agonists have been shown to enhance 
schizophrenia-like symptoms (Randrup and Munkvad, 1967).
In contrast, antipsychotic drugs are not as effective against negative 
symptoms (Keefe et al., 1999), suggesting that an up-regulation of 
dopamine D2 transmission could be only partially responsible for the 
psychiatric symptoms of schizophrenia.
Further studies concerning the role of D2, D3 and D4 subtypes in the 
neurochemistry of schizophrenia have been subject to conflicting results 
(Malmberg et al., 1993).
6
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Glutamate hypothesis. Reduced glutamate levels in the cerebrospinal 
fluid of schizophrenic patients raised the question of a hypofunctionality 
in glutamate transmission (Kim et al., 1980), although this finding was 
not replicated. Moreover, studies on the NMDA receptor antagonists 
ketamine and phencyclidine, showed a pattern of cognitive impairment 
similar to the one observed in schizophrenia (Javitt and Zukin, 1991). 
Thus, a possible role of glutamate has been implicated in 
schizophrenia.
Serotonin hypothesis. Despite the close interrelationship between 
serotoninergic and dopaminergic systems and the fact that atypical 
antipsychotics show 5-HT antagonism, none of the serotonin receptor 
subtypes investigated have been clearly related to the pathogenesis of 
schizophrenia (Veenstra-VanderWeele et al., 2000)
GABA hypothesis. Data from post-mortem studies suggesting a 
reduction in GABAergic function in schizophrenic patients (Perry et al., 
1979) led the research towards the development of a GABA agonist 
effective in the treatment of schizophrenia. However, no consistent 
results have been reported to date.
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1.2 Antipsychotic drugs
Antipsychotics medications are a class of drugs mainly used for the 
symptomatic treatment of psychosis including schizophrenia, mania, 
bipolar disorder and many other conditions characterized by agitation 
and altered mental status. A common feature of these drugs is the 
antagonistic activity at dopamine D2 receptors in the central nervous 
system but other receptors are involved in their mechanism of action 
including D1 and D4 in addition to serotonin (5HT), a-adrenergic, 
cholinergic and histaminic receptors (Arnt and Skarsfeldt 1998).
The first generation of antipsychotic agents, also designated as 
‘neuroleptic’ or ‘typical’, are potent dopaminergic D2 antagonists that 
have a strong propensity towards producing extrapyramidal side effects 
(EPSEs) arising from activity in the striatum. In contrast, the so-called 
newer generation of antipsychotics exhibits much less marked EPSEs 
and for this reason are named ‘atypical’.
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1.2.1 History
The history of antipsychotic medications was pioneered by the 
development of phenothiazine compounds as industrial dyes (i.e. 
methylene blue) at the end of 19th century. Subsequently, in the 1930s, 
one of these compounds, promethazine, was found to have 
antihistaminic and sedative properties and, following tests on rodents, it 
was found to prolong sleep induced by barbiturates. It was introduced 
by Laborit in the clinic for its ability to prolong and stabilize anaesthesia 
for surgery (Laborit et al.,1952).
A few years later, another significant phenothiazine derivative was 
synthesized by Charpenter and later tested by Laborit. This compound, 
named chlorpromazine, was found to reduce anxiety and induce mild 
sedation without causing loss of consciousness, which led to its use in 
the treatment of psychosis in France by Delay and Deniker (Delay and 
Deniker, 1952) and later, chlorpromazine was licensed in the USA in 
1955.
9
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1.2.2 First generation antipsychotics (typical)
The typical antipsychotics are commonly divided into three main 
categories that reflect different classes of chemical structure: (a) 
phenothiazine, (b) thioxanthines and (c) butyrophenones.
First generation antipsychotics are also classified on the basis of their 
relative potency as low, medium and high potency, according to the 
dosage necessary to cause an antipsychotic effect. Aliphatic 
phenothiazines such as chlorpromazine are designated as ‘low- 
potency’, while piperazine phenothiazines such as fluphenazine and 
trifluoperazine, thioxanthines and butyrophenones are referred to as 
‘high potency’ antipsychotics.
1.2.2.1 Pharmacology
A prominent feature of all the first generation antipsychotics is 
antagonism at the D2-subtype of dopamine receptors in the CNS. 
Although these drugs possess different affinities at D1, D4, serotonin 
5HT2, histamine H1, adrenergic and cholinergic receptors, it appears
10
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that D2 antagonism represents a major component of their 
antipsychotic activity (Seeman, 1980).
While dopamine is ubiquitous in the central nervous system, particularly 
in the nucleus caudate (nigrostriatal system), nucleus accumbens 
(mesocortical system), the mesolimbic system and the 
tuberoinfundibular pathway, dopamine D2 receptors localized in the 
limbic and striatal areas are implicated in antipsychotic efficacy and 
EPSEs.
1.2.2.2 Efficacy
Conventional first generation antipsychotics are not the current first 
choice for the treatment of schizophrenia and although they are 
effective in first-episode schizophrenia, especially in improving the 
positive symptoms, they are not superior to atypical agents such as 
clozapine (Lieberman et al., 2003). Although chlorpromazine and 
haloperidol reduce the risk of relapse (Thornley et al., 2003; Joy et al., 
2001), they are not effective in refractory schizophrenia compared to 
second-generation antipsychotics (Kane et al., 1988).
11
Chapter 1
At present, treatment with typical agents is only recommended for 
patients showing a good clinical response with minimal side effects 
(Sharif, 1998).
1.2.2.3 Neurological Side effects
Due to the blockade of the dopamine D2 innervations in the striatum, 
the conventional antipsychotics generate a range of neurological 
adverse effects that are much less marked or even absent in the case 
of the newer generation drugs. While akathisia, dystonia, parkinsonism 
and neuroleptic malignant syndrome represent acute reactions to these 
medications, tardive diskinesia can occur after chronic treatment. 
Akathisia is a syndrome characterized by a strong feeling of physical 
and psychological discomfort, a classic feature is patient agitation and 
anxiety, restless leg and a need to maintain constant movement that is 
difficult to control voluntarily (Sachdev and Loneragan, 1991).
Dystonic reactions typically involve muscular contractions and spasms 
generally limited to the face, neck and back resulting in abnormal
12
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posture (Van Harten et al., 1999). These are the first symptoms to 
appear in response to antipsychotic therapy.
The symptoms observed in drug-induced parkinsonism are virtually the 
same as those seen in idiopathic Parkinson disease: bradykinesia, 
rigidity, inability to initiate movement, tremor and a mask-like face.
The neuroleptic malignant syndrome is a rare condition compared to the 
other symptoms outlined previously. Symptoms include catatonia, 
rigidity, fever, high blood pressure and a high level of creatine kinase 
(Adnet et al., 2000). Given the high rate of mortality caused by this 
condition, immediate cessation of the antipsychotic therapy is required. 
After long-term treatment with conventional antipsychotics, tardive 
dyskinesia may appear. Typical symptoms are exemplified by 
involuntary movements of the face, tongue, neck and limbs, stereotyped 
movements, muscular spasms and akathisia (Marsalek, 2000).
1.2.2.4 Endocrine effects
Conventional antipsychotics have long been recognized to elevate 
blood levels of the hormone prolactin. In fact, since the stimulation of
13
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the D2 receptors in the tuberoinfindibular area suppresses prolactin 
release, all antipsychotics, particularly those acting in that brain area, 
cause some degree of hyperprolactinaemia via D2 antagonism. As a 
consequence, hyperprolactin-related side effects such as 
gynaecomastia, galactorrhoea and erectile dysfunction may occur 
(Haddad and Wieck, 2004).
Allied to the high levels of prolactin induced by antipsychotics, these 
drugs are also subject of investigation with regard to their potential 
contribution to the development of bone mineral density loss, which has 
been reported in several studies (Liu-Seifert et al., 2004; Meaney et al., 
2004; Meaney and O’Keane, 2007; Kishimoto et al., 2008) and breast 
cancer (Harvey et al., 2008).
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1.2.3 Second generation antipsychotics (atypical)
1.2.3.1 History
The history of atypical antipsychotics began with the discovery of 
clozapine and its antipsychotic properties.
Clozapine was introduced to the market in the 1960s and while the 
chemical structure first suggested that it might posses a potential effect 
as an antidepressant, it was soon discovered that it actually had 
neuroleptic properties (Hippius, 1989). However, there was an anomaly 
reported about this finding because clozapine yielded antipsychotic 
activity without causing EPSEs and this stimulated interest in the nature 
of this drug. In fact, at that time, the onset of EPSEs was considered an 
inseparable pre-requirement for antipsychotic activity (Hippius, 1989). 
Nevertheless, clozapine was marketed in several European countries 
until a study conduced in Finland in 1975 reported several cases of 
agranulocytosis resulting from treatment (Idaanpaan-Heikkila et al., 
1975). Clozapine was then withdrawn from the clinical use, but in the 
following years its unique properties were extensively investigated until
15
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the validation of its efficacy in treating resistant-schizophrenia was 
established, leading to the reappearance on the market in 1990.
1.2.3.2 ‘Atypicality1
Soon after clozapine returned to the market, a new generation of 
antipsychotic drugs, called ‘atypical’, was developed and marketed. 
Amongst these olanzapine, quetiapine, risperidone, ziprasidone and 
aripiprazole were introduced into clinical usage.
Atypical, in general terms, refers to the ability of this new drug class to 
produce a substantial reduction of EPSEs and high levels of prolactin 
compared to the first-generation antipsychotics. However, recent 
studies have demonstrated that atypical antipsychotics are not superior 
to typicals in ameliorating psychotic and negative symptoms (Carpenter 
and Buchanan, 2008).
16
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1.2.3.3 Clozapine
CH3
Fig 1.1 Chemical structure of clozapine
Clozapine, to date, is the only antipsychotic drug that clearly exhibits its 
superiority in treatment-resistant schizophrenia compared to the other 
antipsychotic drugs and this was demonstrated by Kane et al., in 1988. 
Patients who had already received treatment with three different 
antipsychotics and did not respond were randomly given either 
clozapine or chlorpromazine. 30 % of those receiving clozapine 
improved in terms of both positive and negative symptoms against 4 % 
of those who were given chlorpromazine (Kane et al.,1988).
Later studies validated the efficacy of clozapine in patients with a 
history of poor response to other treatments. In a meta-analysis 
involving 12 controlled studies (seven of them comparing clozapine to 
typical antipsychotics), clozapine was shown to be more effective in
17
Chapter 1
treatment-resistant schizophrenia (Chakos et al., 2001). It was also 
more effective than haloperidol in reducing positive symptoms (Kane 
2001 et al.,; Volarka et al., 2002), and also superior to risperidone 
(Azorin et al., 2001) in this respect.
McEnvoy et al., (2006) compared switching to clozapine with switching 
to olanzapine, quetiapine or risperidone, and showed that clozapine 
was more effective, with a longer time of discontinuation compared to 
the other drugs.
Moreover, in a 52-week study, clozapine was tested against 
chlorpromazine in 160 first-episode schizophrenia patients and the 
clozapine-treated patients showed faster remission (Lieberman et al., 
2003). Clozapine also proved to be effective in reducing aggressive 
behavior in patients with schizoaffective disorder (Krakowsky et al., 
2006), in childhood-onset schizophrenia (Shaw et al., 2006; Kumra et 
al., 2008) and in the treatment-resistant bipolar disorder and mania 
(Green et al., 2000).
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In addition, it was also effective in reducing substance abuse and 
conditions associated with suicidal risk among schizophrenic patients 
(Iqbal et al., 2003).
Mechanism of action of clozapine
The pharmacology of clozapine is rather complex due to the interaction 
with a wide range of receptor families. Which of these interactions is 
responsible for its unique properties, particularly in treatment-resistant 
schizophrenia, has yet to be elucidated.
Clozapine appears to have relative low affinity for all the dopamine 
receptor subtypes (compared to conventional agents) with the 
exception of D4. Thus, radioligand binding data has shown that 
clozapine possesses moderate to low affinity for D1 receptors in the 
striatum although functional studies unveiled differing degrees of D1 
receptor occupancy (Ashby and Wang, 1996).
PET studies on the occupancy of D2 receptors in the striatum of 
schizophrenic patients revealed that clozapine occupancy was 48%, 
which was significantly less than the typical antipsychotics (Fame and 
Nordstrom, 1992), leading to the hypothesis that this may contribute to
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its atypical profile. Clozapine also possesses low affinity for D3 
receptors (Ashby and Wang, 1996) but in contrast, it displays high 
affinity for the D4 subtype and antagonist at this site is thought to exert, 
at least in part, its therapeutic effect (Van Tol et al., 1991).
Furthermore, clozapine displays some 5HTia affinity, strong affinity for 
5HT2c and potent 5HT2A antagonism, which coupled with low affinity for 
D2 receptors, has been proposed as possible explanations for its 
pharmacological properties (Meltzer, 1989). In addition, clozapine also 
displays some affinity for 5HT6 and 5HT7 receptors (Bymaster et al., 
1996).
Clozapine binds with high affinity to muscarinic receptors (Miller and 
Hiley, 1974), and it has been established as an antagonist at M1, M2, 
M3 and M5 subtypes and also an M4 agonist (Zorn et al., 1994). More 
recently however, it has been reported that clozapine behaves as a 
partial agonist at M1, M2 and M3 subtypes (Olianas et al., 1999). 
Clozapine also binds with high affinity to histaminergic H1 receptors, 
while binding and functional studies indicate that it is a potent
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ai adrenoreceptor antagonist with low to moderate affinity for a2 
adrenoreceptors (Ashby and Wang, 1996).
1.2.3.4 Olanzapine
Fig 1.2 Chemical structure of olanzapine
Being similar to clozapine in both chemical structure and 
pharmacological profile, olanzapine also shares a similar pattern of 
clinical use and is one of the most common atypical antipsychotic 
employed in clinical practice.
In several short-term trials olanzapine exhibited superiority to 
haloperidol in overall symptoms improvement, safety profile and in 
numbers of patients who discontinued the treatment (Tollefson et
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al.,1997), in first-episode schizophrenia (Sanger et al., 1999) and in 
poor responding patients (along with clozapine) (Volavka et al., 2002).
In contrast, results from 12 week-acute phase treatment of first-episode 
psychosis produced little difference in symptoms severity compared to 
haloperidol but better compliance to the treatment regime (Lieberman et 
al., 2003).
Furthermore, a review of several randomized trials indicates that 
olanzapine is superior to both first and second-generation 
antipsychotics in terms of adherence to the treatment and longer time to 
discontinuation (Johnsen and Jorgensen, 2008). Olanzapine also 
appeared to be more effective than aripiprazole, quetiapine, risperidone 
and ziprasidone in a recent meta-analysis (Leuch et al., 2009). 
Olanzapine has been further studied in comparison with risperidone and 
it generated a higher general response to the treatment (Breier et al., 
2005) particularly against negative symptoms (Canive et al., 2006) as 
well as being more effective when compared to switching to quetiapine 
(Deberdt et al., 2008).
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Olanzapine manifests to have longer time to discontinuation (Beasley et 
al., 2007), and in the maintenance of response (Stauffer et al., 2009) 
compared to other antipsychotics. Its effectiveness was also observed 
in the treatment of bipolar disorder (Derry and Moore, 2007; 
Nabasimhan et al., 2007) and in adolescents suffering bipolar mania 
(Tohen et al., 2007).
Mechanism of action of olanzapine
Olanzapine exhibits a similar pharmacological profile to clozapine. 
Hence, it displays a potent receptor blockade at 5HT2A, 5HT2c and 
5HT6, muscarinic M1, H1 and a r adrenoceptors, although the 
ad renoreceptor affinity is lower than clozapine. Olanzapine also 
possesses higher affinity for D1 and D2 receptors but lower affinity for 
D4 than clozapine (Bysmaster et al., 1996).
1.2.3.5 Non-neurological side effects: weight gain and metabolic 
syndrome
Numerous studies have shown that schizophrenic patients have a 
greater propensity towards obesity than the general population and
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obesity occurs more frequently in atypical antipsychotic-treated patients 
than those on conventional antipsychotics (Aquila, 2002). Interestingly, 
the incidence of weight gain among the new generation of these drugs 
is variable.
Despite being among the most effective antipsychotic drugs in clinical 
practice, clozapine and olanzapine are in fact, associated with the 
greatest incidence of weight gain compared to the other atypical 
antipsychotics.
The first meta-analysis to show that clozapine and olanzapine cause 
the greatest weight gain was conducted in 1999; clozapine displayed a 
mean weight gain of 4.45 kg during the treatment, olanzapine 4.15 kg, 
risperidone 2.10 kg and ziprasidone 0.04 kg (Allison et al., 1999).
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10-W eek W eight Gain
Fig 1.3 Weight change after 10 weeks on different antipsychotic drugs. 
(Modified from Allison et al., 1999 and Newcomer et al., 2004).
In another study, 20 % of the patients treated with clozapine gained 
more than 10 % of their body weight between 12 weeks and 12 months 
of treatment and although most the body weight increased during the 
first 4-12 weeks, further increases occurred following clozapine 
treatment. After 52 weeks, 20 % of the patients gained a further 20 % of 
their body weight (Iqbal et al., 2003).
In a retrospective study where 82 patients treated with clozapine were 
followed for up to 90 months, more than 50 % of them became 
overweight with a higher relative increase among patients who were 
underweight or normal weight at baseline (Umbricht et al., 1994).
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Several studies reviewed by Nasrallah et al., (2008) showed that over 
one year clozapine and olanzapine caused a mean weight gain of 12 
kg, against an increase of 2-3 kg for risperidone and quetiapine, and 1 
kg for ziprasidone.
Likewise, olanzapine caused greater weight gain compared to 
quetiapine, risperidone, perphenazine and ziprasidone with a large 
proportion of patients gaining 7 % of their body weight or more 
(Lieberman et al., 2005). A similar degree of olanzapine-induced body 
weight increase has also being reported by Beasley (1997).
Weight gain, when associated with the development of obesity 
(estimated using the body mass index BMI) and abdominal fat 
deposition is often the cause of impaired glucose regulation, insulin 
resistance, hypertension and dyslipidemia, all risk factors that may 
result in the development of diabetes and cardiovascular disease 
(CVD). The presence of at least three of the above mentioned factors is 
known as metabolic syndrome (Van Gaal, 2006).
Furthermore, patients with mental illnesses are recognized as having a 
high rate of type 2 diabetes and incidence of CVDs that in turn leads to
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an increased risk of mortality associated with these conditions (Casey 
et al., 2004). In fact, clozapine and olanzapine treatment appears to 
enhance plasma glucose level and evoke insulin resistance in non­
diabetic patients with schizophrenia compared to healthy subjects and 
those treated with other antipsychotics (Newcomer, 2004). This finding 
has been confirmed in a subsequent meta-analysis of 14 studies 
examining the association between diabetes onset and treatment with 
atypical antipsychotics in comparison with typicals or absence of 
treatment (Newcomer, 2007).
Moreover, olanzapine and clozapine have been shown to increase the 
risk of developing hyperlipidemia in comparison with other second- 
generation antipsychotics (Lambert et al., 2005).
1.2.3.6 Weight gain and antipsychotic noncompliance
Despite the fact that weight gain has been recognized as a side effect 
of antipsychotic drug treatment for a long time, only in the past decade 
has its importance been appreciated. Previously, the significance of the 
weight gain was often underestimated because it was associated with a
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largely disregarded effect of the illness itself relative to other 
antipsychotic side effects (Allison et al., 1999). The introduction of the 
second generation of these drugs and the reduction of the incidence of 
EPSEs allowed a focus on other side effects such as the increase in 
weight.
Weight gain and metabolic abnormalities are in fact, a cause of major 
concern in clinical practice. A number of studies have demonstrated 
that compliance with antipsychotic medication is generally poor and not 
taking medication is associated with a substantial increase in 
rehospitalisations and a generally poorer outcome. Noncompliance 
inclines patients to relapse, leading to significant psychological distress, 
medical morbidity and increased mortality (Fontaine et al., 2001).
In a recent study, a significant, positive association was found between 
the patient’s increase in weight and subjective distress and medication 
non-compliance. Moreover, a higher baseline BMI was associated with 
a 2.5 fold increase in the likelihood of stopping medications (Weiden et 
al., 2004).
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Furthermore, psychotic patients tend to smoke more than the general 
population and the impact of weight gain and all the metabolic 
abnormalities related to it may be underestimated by the fact that they 
are less likely to receive medical treatment for non psychiatric-related 
illnesses (Fontaine et al., 2001).
Over the years, clozapine and olanzapine have gained much popularity 
as treatment options especially in the light of the role of clozapine as 
the only effective treatment for refractory schizophrenia. However, they 
appear to have the greatest weight gain propensity and as far as 
clozapine is concerned, the cumulative incidence of all patients 
reaching 20 % overweight, representing a significant long-term health 
risk, has been reported to be greater than 50 % (Umbricht et al., 1994). 
Similarly, clozapine gives the highest incidence of diabetes and 
hyperlipidemia.
Interestingly, while treatment with clozapine reduced the risk of suicide 
by 80-85 % in treatment resistant-schizophrenic patients (Meltzer, 
1999), a recent estimate of the consequences of drug-induced weight 
gain and diabetes concluded that its benefit in preventing suicide “may
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essentially be offset by the deaths due to weight gain” (Fontaine et al., 
2001).
The above effects on compliance coupled with the morbidity and 
mortality associated with antipsychotic induced obesity and 
hyperglycemia clearly highlights the need for adjunctive intervention to 
improve the health of patients treated with atypical antipsychotic drugs.
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1.3 Aims of the project
Given the relevance of atypical antipsychotic-induced side effects in the 
clinic, it is vital to study the biological basis underlying metabolic side 
effects using animal models and in-vitro and ex-vivo cell models.
Thus, the aims of the project are:
1. Initially, to develop a reliable and consistent mouse model of
olanzapine and clozapine induced-weight gain and augmented
adiposity which will mimic the increase in body weight and fat
deposition seen in the clinic. The development of such a model would 
not only facilitate the testing of possible adjunctive treatments to 
counteract atypical antipsychotic-induced side effects but would also 
prompt further research to uncover the mechanisms responsible for 
them.
2. In addition, to correlate with the above investigation, cultured 
fibroblastic-like cells 7-F2 and primary bone marrow cells will be 
employed as a model to study adipogenesis. The principal goal of this 
study will be to probe the likelihood that clozapine and olanzapine might
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produce a direct peripheral effect on adipocyte formation and/or perturb 
lipid metabolism.
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2. Materials and methods
2.1 Animal model
2.1.1 Animal husbandry
Female mice C57BL/6J, aged 4-5 weeks, purchased from B&K (UK), 
were used in the animal studies. On the arrival animals were housed as 
two per cage to avoid social isolation. They were kept under standard 
conditions of husbandry receiving pellet mouse food and water ad 
libitum.
Room temperature was maintained at 20.0 ± 1.5 °C in humidity- 
controlled conditions and the lighting was on a 12 h/12h light/dark cycle. 
Animals were acclimatized for a week before commencement of 
experiments, during which time they were handled daily for habituation.
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The use of animals in these studies was carried out in accord with UK 
Home Office licensing, as prescribed by The Animals (Scientific 
Procedures) Act 1986.
2.1.2 Drug treatments
Clozapine and olanzapine were purchased from Kemprotec Ltd, 
(Middlesbrough, UK).
The drug was offered orally to the animals once a day at the stated 
doses in the morning. The vehicle consisted of pure honey (Tesco, UK).
2.1.3 Methodology
Animals were self-administered with honey (as the drug vehicle) or the 
drug mixed with honey placed inn a small plastic Petri dish (2.5 cm 
diameter) on a trial basis for 15 minutes daily over a 28-day period (plus 
a 5-day period of habituation).
During drug self-administration, animals were housed individually. Each 
particular animal was checked to ensure consumption of the drug or 
vehicle.
Treatment 1: Effect of olanzapine 10 mg/kg on body weight and fat 
deposition.
Two groups of mice (n=12 per group) were food deprived for 5 hours, 
then given 0.1 ml of honey mixture with 0 (control) or 10 mg/kg of 
olanzapine once a day orally for 28 days.
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Treatment 2: Effect of olanzapine 5 and 15 mg/kg on body weight 
and fat deposition.
Three groups of mice (n=10) were given 0.1 ml of honey mixture with 0 
(control), 5 or 15 mg/kg of olanzapine once a day orally for 28 days.
Treatment 3: Effect of clozapine 4 and 8 mg/kg on body weight and 
fat deposition.
Three groups of mice (n=10) were given 0.1 ml of honey mixture with 0 
(control), 4 or 8 mg/kg of clozapine once a day orally for 28 days.
Treatment 4: Effect of clozapine 15 and 25 mg/kg on body weight 
and fat deposition.
Three groups of mice (n=10) were given 0.1 ml of honey mixture with 0 
(control), 15 or 25 mg/kg of clozapine once a day orally for 28 days.
Treatment 5: Effect of clozapine 15 mg/kg, metformin 500 mg/kg, 
and clozapine 15 mg/kg + metformin 500 mg/kg on body weight 
and fat deposition.
Four groups of mice (n=9) were given 0.1 ml of honey mixture 
containing 0 (control), 15 mg/kg of clozapine, 500 mg/kg of metformin or 
clozapine 15 mg/kg + metformin 500mg/kg once a day orally for 28 
days.
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Treatment 6: Effect of clozapine 15 and 25 mg/kg and olanzapine 
10 and 12.5mg/kg on body weight and fat deposition.
Five groups of mice (n=7) were given 0.1 ml of honey mixture with 0 
(control), 15 or 25 mg/kg of clozapine and 10 or 12.5 mg/kg of 
olanzapine once a day orally for 28 days.
2.1.4 Measurements
Body weight was recorded every morning prior to the start of treatment. 
At the end of each 28-day experiment, animals were killed under 
terminal gaseous anaesthesia.
White adipose tissue from perirenal, periuterine and intraabdominal 
areas were dissected out, pooled and weighted.
Bone marrow was collected from femur bones. The femur bones were 
dissected out, separated from their attached muscle and connective 
tissue, then cut at both ends and bone marrow flushed with RNAse-free 
water (Ambion, UK), then stored in RNA later (Ambion, UK) at -20 C 
until required for qRT-PCR analysis.
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2.1.5 Quantitative Real Time-PCR
RNA from bone marrow was extracted using Trizol reagent, then cDNA 
was reverse transcribed from total RNA samples using random primers 
and the PCR products were subsequently synthesized from cDNA 
samples using the PCR mastermix.
2.1.5.1 RNA extraction and quantification
Total RNA was extracted with Trizol according to manufacturers 
instructions. This reagent isolates high quality RNA from the biological 
material; it combines phenol and guanidine thiocyanate in a mono­
phase solution to facilitate the immediate and most effective inhibition of 
RNAse activity. The biological sample was homogenized in Trizol then 
separated into aqueous and organic phases by chloroform addition 
followed by centrifugation (RNA remains in the aqueous phase, DNA in 
the interphase and proteins in the organic phase). RNA was 
precipitated by addition of isopropanol, then washed with ethanol and 
subsequently solubilised.
The frozen tissues were homogenized in 1.0 ml of Trizol at room 
temperature using a PowerGen 125 Tissue Homogenizer (Fisher 
Scientific). The homogenates were then transferred to clean tubes and 
left at room temperature for 5 minutes. Chloroform (0.2 ml) was added 
and the tubes vigorously shaken for 15 seconds and incubated at room
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temperature for 2 minutes. The samples were then centrifuged at 
12,000 x g for 15 minutes at 4 °C.
After centrifugation the colourless upper aqueous phase was 
transferred to clean tubes and mixed with 0.5 ml of isopropanol and 
stored overnight at -20 °C.
The samples were then centrifuged at 12,000 x g for 15 minutes at 4 
°C. The RNA precipitate forms a white pellet on the side and bottom of 
the tube. Pellets were then washed twice with 1.0 ml of 75% ethanol 
and centrifuged at 12,000 g for 10 minutes at 4 °C.
Ethanol was then removed and RNA pellets air-dried for 5 minutes. 
Pellets were resuspended in 20 \i\ in RNAse-free water and stored at - 
80 °C.
RNA quantity was determined on a Beckman UV-DU64 
spectrophotometer by measuring optical density at 260 nm wavelength. 
The ratio between the absorbance values at 260 and 280 nm gave a 
measure of RNA purity. A 260/280 ratio between 1.6 and 2.0 indicated 
a sample of sufficient purity.
The integrity of each RNA sample was confirmed using Agilent 
BioAnalyzer.
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2.1.5.2 Reverse Transcription Reaction (RT)
cDNA was reverse transcribed from 1 p,g of total RNA using random 
primers (High Capacity cDNA Reverse Transcription Kit, Applied 
Biosystems, UK).
The following reaction was set up in individual tubes:
RT mastermix Volume/reaction
10X RT Buffer 2 pi
25X dNTP mix (100mM) 0.8 pl
10X RT random primers 2 p,l
Multiscribe Reverse Transcriptase 1 pi
RNAse Inhibitor 1
Nuclease-free Water 3.2 pi
Table 2.1a Volumes of regents used for RT 
Tubes were placed on ice and mixed with the following mix:
RNA sample Total amount Volume/reaction
RNA 1 MO Xpl
Nuclease-free water - Up to 10 pi
Table 2.1b Concentrations and volumes of reagents used for RT
Negative controls, containing water instead of RNA, were also prepared 
to verify that none of the kit reagents was contaminated with DNA.
The RT reaction was carried out at the following thermal profile: 25 °C * 
10 minutes / 37 °C * 120 minutes / 85 °C * 5 minutes.
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The cDNA was then stored at -20 °C.
2.1.5.3 qRT-PCR procedure
Quantitative Real Time-PCR was performed using the 7900HT Fast 
Real-Time PCR system and TaqMan gene expression assay (AB 
Applied Biosystems, UK).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
the housekeeper gene. Pre-designed and labeled primers/probe sets 
were purchased from AB Applied Biosystems.
For each gene, the following qPCR mix was prepared in 96-well PCR 
plate:
qPCR mix Volume/reaction
TaqMan Universal PCR master mix 10|il
dH20 5 |xl
Gene expression assay solution 1 pl
Table 2.2 Volumes of regents used for qPCR
cDNA (4 |il) was added to the qPCR mix (4 \i\ of dhfeO for non-template 
control). The plate was then centrifuged briefly and the reaction was 
carried out at the following thermal profile: 95 °C x 10 minutes/ 95 °C x 
15 seconds + 60 °C x 1 minute (40 cycles).
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All the reactions were performed in triplicate and results were 
normalized relative to GAPDH expression control. The results were 
expressed in terms of relative quantification (RQ). RQ determines the 
changes in expression of a target sequence in a test sample relative to 
the same sequence in a calibrator sample.
The RQ expression of the genes of interest was analyzed using SDS 
software, Sequence Detection System (Applied Biosystems).
2.1.6 Statistical analysis
Statistical analysis was performed using Statistical Package for Social 
Science (SPSS) version 12. Data from weight gain experiments were 
analyzed employing statistical comparison between means and 
repeated measures analysis of variance (ANOVA), followed by 
Dunnett’s post-hoc. If comparison was made between two groups 
Mann-Whitney test was used. For the qRT-PCR experiment statistical 
comparison between means and student t test was used. The criteria 
for statistical significance was P< 0.05. Data are presented as means ± 
SEM.
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2.2 Cell culture
2.2.1 Cell line
The 7-F2 cell line derives from the bone marrow of p53 knockout mice. 
Thompson et al., (1998) isolated and characterized ten clonal cells lines 
which were grouped into three categories, one of the clones gave rise 
to the 7-F2 cell line, characterized by indefinite growth in vitro and 
mesenchymal origin.
The 7-F2 cells were kindly donated by Dr. Browen Evans (Department 
of Child Health, School of Medicine, Cardiff University) and used at 
passage 10-30.
2.2.2 Cell husbandry
Full culture medium: alpha minimum essential medium containing 
Earle’s salt, sodium pyruvate 1mM and L-glutamine 2 mM, without 
ribonucleosides and dexoxyribonucleosides, supplemented with 10 % 
v/v fetal bovine serum (FBS), 100 ng/ml of streptomycin and 100 U/ml 
of penicillin.
Adipocyte differentiation medium: the above a-MEM medium was 
supplemented with 50 mM of indomethacin, 50 mg/ml of ascorbic acid 
and 100 nM dexamethasone to induce adipocyte differentiation 
(Thompson 1998).
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The full culture media as prepared above was kept refrigerated at 4 °C 
and warmed at 37 °C in a water bath prior to use.
All cell culture ingredients were purchased from Gibco (Invitrogen UK). 
Indomethacin, ascorbic acid and dexamethasone were purchased from 
Sigma (UK).
Cells were grown in 25 cm2 flasks in a humidified incubator at 37 °C, 
5% CO2 and 95% air.
When the cells reached confluence, approximately once every 3-4 
days, they were passaged: first, the media was aspirated from the flask 
by vacuum then the cells were washed with sterile phosphate buffered 
saline (PBS), 0.5 ml of trypsin was added and incubated at 37 °C for 3- 
5 minutes. Once the cells were detached from the bottom of the flask, 
trypsin was inactivated by adding 2 ml of full media, then cells were 
centrifuged for 3 minutes at 1000 x g, the supernatant was discarded 
and the cells resuspended in 1.0 ml of full media to be either seeded in 
new flasks (ratio 1:5) or in a known volume of media in order to be 
seeded at a known density in 6,12 or 96 well plates.
To seed the cells at a specific density, cells were counted in a 
haemocytometer: 8 \i\ of cell suspension was transferred to both 
chambers of a haemocytometer and an average count of 10 squares in 
each of the chambers (x 104) provided the number of cells per ml. Once 
the cell number was determined, an appropriate volume of full media
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was added to a known volume of cell suspension to obtain the desired 
cell seeding density.
2.2.3 Drug exposure
Cells were incubated with clozapine or olanzapine (Kemprotec, UK) at 
the appropriate concentration while control cells were incubated in full 
media containing the appropriate volume of DMSO vehicle.
2.2.4 MTS proliferation assay
For this assay, at day -1, cells were seeded in 96-well plates at the 
density of 3,000 cells per well in a volume of 100 pl of full media. At day 
0, full media was replaced with media containing the test-drugs at 
several different concentrations and then cells were incubated at 37 °C 
for 72 hours, 5 days or 7 days.
The MTS assay is based on the conversion of the tetrazolium salt MTS 
(3-(4,5-dimethylthiazol-2yl-)-5-(3-carboximethoxyphenyl)-2-(4- 
sulphophenyl)-2H-tetrazolium, inner salt) into a coloured and water- 
soluble formazan.
The dehydrogenase enzymes of the viable cells reduce the yellow MTS 
solution to a purple colour at 37 °C. Therefore, the amount of formazan 
produced is directly proportional to the number of living cells providing a 
good indication of cell viability (Malich et al., 1997).
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The MTS reagent (Promega, UK) was combined with a detection 
reagent, phenazine methosulfate (PMS) (Promega, UK), in ratio of 20:1, 
then the mixture was added to the cell culture in a ratio of 1:5 (20 pil). 
The plate was then covered in alluminium foil since the reagent is light 
sensitive, and incubated at 37 °C for 1.5 hours.
The absorbance was measured in a microplate spectrophotometer at 
490 nm.
2.2.5 Cell counting with haemocytometer (trypan blue exclusion)
The haemocytometer is a device used to estimate cell number. It 
consists of a thick glass slide, which has a central H-shaped chamber 
carrying two grid compartments of known area and volume. Each 
compartment is divided into 9 squares each covering an area of 1 mm2 
(Fig 2.1). After the cover glass is applied on the top of the chamber, a 
known volume of cell sample is applied by pipette in the compartments 
through the edge of the cover glass. The cells lying on the central 
square, top left and top right, bottom left and bottom right squares are 
counted (cells lying on the bordering lines are counted if they are on 
either the top or on the left lines only). The number of cells in 1 ml of the 
original sample is counted as follow:
Total number of cells in each square X 104 
Number of squares
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Fig 2.1 A haemocytometer
http.y/toolboxes.flexiblelearning. net.au/dem osites/series4/412/laboratorv/studv 
notes/SNHaemo.htm
For this assay, at day -1, cells were seeded in 6-well plates at the 
density of 30,000 cells per well in a volume of 1 ml of full media. At day 
0, the general media was replaced with the media containing the test- 
drugs at several different concentrations and then the cells were 
incubated at 37 °C for 72 hours.
The cells were then washed with PBS, trypsinized, centrifuged and then 
resuspended in 100 pi of full media; to the cell suspension an equal 
amount of trypan blue solution 0.4%, 100 pi, was added. The mixture 
was then left to incubate for 5 minutes at room temperature and then 
placed in haemocytometer for manual cell counting.
Trypan blue is a dye that stains selectively dead cells, therefore, non- 
viable cells will appear blue under the light inverted microscope.
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2.2.6 Adipocyte differentiation assay
For this assay, at day -1, cells were seeded in 12-well plates at the 
density of 15,000 cells per well in a volume of 0.5 ml of full media. At 
day 0, the media was replaced with the adipocyte differentiation media 
(described in 2.2.2) with or without the test-drugs at different 
concentration and the cells were then incubated for 2, 5 and 8 days 
before proceeding with staining and quantification. The media in each 
well was changed every 3 days.
Oil Red O Staining
Oil Red O stock solution was prepared by dissolving 0.25 g of Oil Red 
O (Sigma, UK) in 50 ml of isopropanol. The working solution consisted 
of a mixture 3:2 of the stock solution-dH20.
Firstly, the cells were washed with 1.0 ml of PBS then fixed in 0.5 ml 
formal saline (10% formaldehyde in 0.9% NaCI) for 15 minutes. The 
formal saline was subsequently removed and cells were washed with 
distilled water. The cells were then stained with 400 pi of Oil Red O 
solution for 20 minutes.
Excess stain was washed off with 80 pi of 60% isopropanol followed by 
further washing with 1.0 ml of PBS. The cells were then stored in fresh 
PBS prior to qualitative microscopy.
To quantify the adipogenesis (in terms of concentration of Oil Red O), 
250 pi of isopropanol was added to each well to dissolve the stain and
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the plate shaken briefly; then 150 \i\ from each well was transferred to a 
96-well plate and absorbance was read in a microplate 
spectrophotometer at 490 nm.
2.2.7 Quantitative Real Time-PCR
7-F2 cells were differentiated for 5 days then total RNA was extracted 
using Trizol reagent (Invitrogen), 1 \xg of RNA was subsequently 
reverse transcribed into cDNA using random primers (Improm II, RT 
system, Promega, UK).
The expression of genes of interest was determined relative to 
housekeeper gene acid ribosomal protein (ARP).
2.2.7.1 RNA extraction and quantification
Cells, seeded in 6 well plates, were lysed with 1 ml of Trizol reagent 
and homogenized by pipetting up and down. The homogenates were 
then transferred to 1.5 ml tubes and incubated at room temperature for 
5 minutes to permit the complete dissociation of nucleoprotein 
complexes.
The homogenates were mixed with 0.2 ml of chloroform and the tubes 
shaken vigorously by hand for 15 seconds then incubated at room 
temperature for 3 minutes. Samples were centrifuged at 12,000 x g for 
15 minutes at 4 °C.
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Following centrifugation, the mixture separated into a lower red, phenol- 
chloroform phase, an interphase and a colourless upper aqueous phase 
(containing RNA).
The aqueous phase was transferred to a fresh tube and RNA 
precipitated by mixing with 0.5 ml isopropanol. Samples were incubated 
at room temperature for 10 minutes and centrifuged at 12,000 x g at 
4°C. After removing the supernatant, the pellet was washed with 1 ml of 
75% ethanol and centrifuged at 7,500 x g for 5 minutes at 4 °C.
At the end of this procedure, the RNA pellet was air-dried and dissolved 
in 25 pi of RNAse-free water by pipetting up and down and then 
incubated for 4 minutes a 55 °C.
DNAse treatment
Contaminating DNA was removed using DNA-free kit (Ambion, UK). 
Samples were mixed with 2.5 pi of 10x DNAse I buffer and 0.5 pi of 
DNAse 1, agitated gently and then incubated at 37 °C for 30 minutes. 
To stop the digestion, the samples were treated with 2.5 pi of DNAse 
inactivation reagent and incubated at room treatment for 2 minutes, 
then centrifuged at 10,000 x g for 2 minutes and the supernatant, 
containing RNA, was transferred to a fresh tube and stored a -80 °C.
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RNA quantification
RNA was quantified by GeneQuant spectrophotometer (GE Healthcare, 
UK).by measuring optical density at 260 nm, and quality was checked 
by the ratio 260/280 nm. The ratio 260/280 nm was ^1.7 for all the 
samples, thus indicating pure RNA.
2.2.7.2 Reverse Transcription Reaction (RT)
Reagents employed in this reaction were supplied by Promega, UK. 
The following reaction was set up in two DNA/RNA-free tubes:
Reagent final concentration volume/reaction
RNA 1 ng X jxl
Random primers (500^g/ nl) 0.5|xg/ |xl v i
Nuclease free water
-
Up to 5pil
Table 2.3a Concentrations and volumes of reagents used for RT
The mix was incubated at 70 °C for 5 minutes then immediately chilled 
on ice. The following reaction was set up in two DNA/RNA-free tubes:
RT mix RT-PCR sample No Enzyme RT-PCR 
control
5x reaction buffer 4\i\ 4\i\
MgCI2 (25mM) 2.4jxl 2A\i\
dNTPs(40mM) V V I
RNAsin 0.5|il 0.5\i\
Reverse transcriptase 0\i\
Nuclease free water 6.1 fil 7. V I
Table 2.3b Volumes of reagents used for RT
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The RNA target + primers was added to the 15 pi above and the mix 
gently pipetted up and down. The RT reaction was carried at the 
following thermal profile: 25 °C * 5 minutes / 42 °C x 60 minutes / 70 °C
x 15 minutes. The cDNA was then stored at -20 C°.
2.2.7.3 Primers design
The primers have been designed by Dr Borzo Gharibi, Department of
Child Health, School of Medicine, Cardiff University.
Primers Forward Reverse Size(bp)
C/EBPp CAAGCTGAGCGACGAGTACA C AG CTGCT CC ACCTT CTT CT 157
PPARy TTTT C AAG G GT G CC AGTTT C AAT CCTTGGCCCT CT GAGAT 220
LPL GCGTAGCAHG AAGT CT G ACC CAT C AG G AG AAAG GCG ACT G 108
ARP GAGGAATCAGATGAGGATATGGGA AAGCAGGCTGACTTGGTTGC 72
Table 2.4 Mouse primer sequences. Acid ribosomal protein (ARP) is used as the 
housekeeper gene.
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2.2.1 A  qRT-PCR procedure
Quantitative Real Time-PCR was performed using an MX300p thermal 
cycler (Stratagene, UK) and Platinum SYBR green qPCR SuperMix 
UDG (Invitrogen, UK).
The following reaction was set up:
Reagent Volume/reaction
SYBR green 12.5 pi
cDNA 1 pi
Forward primers 1 pi
Revers primers 1 pi
Nuclease-free water 9.5 pi
Table 2.5 Volumes of regents used for qPCR
The mixture was prepared in a 96-well PCR plate, centrifuged at 1000 x 
g for 5 minutes and then the reaction was performed using the following 
thermal profile: 50 °C x 2 minutes/ 95 °C x 2 minutes/ 90 °C x 15 
seconds + 60 °C x 30 seconds (45 cycles).
All reactions were performed in duplicate and template negative 
controls were included in the amplification. Results were normalized 
relative to ARP expression control.
The relative quantitative expression of the genes of interest was 
analyzed using MxPro software (Stratagene).
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2.2.8 Statistical analysis
Statistical analysis was performed using SPSS version 12. Statistical 
comparison between means was employed using student t test and 
one- way ANOVA, followed by Dunnett’s post-hoc test.
The criteria for statistical significance was P< 0.05. Data are presented 
as means ± SEM.
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3. Antipsychotic-induced weight gain: a 
preliminary study to develop an animal model
3.1 Introduction
Over the past few years several research groups have attempted to 
develop a rodent model of chronic antipsychotic-induced weight gain 
and metabolic dysregulation in order to reflect the clinical situation. 
Table 3A summaries some of the pertinent results from a number of 
published studies conducted with the aim of developing such a model, 
focusing particularly on the effects of clozapine and olanzapine.
Olanzapine has been shown to produce weight gain in female rats and 
these findings have been replicated in various laboratories (Goudie et 
al., 2002, Pouzet et al., 2003, Arjona et al., 2004, Fell et al., 2004,
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Cooper et al., 2005, Kalinichev et al., 2005-2006, Albaugh et al., 2006). 
However, experiments involving male rats have encountered difficulties 
in reproducing the weight gain caused by antipsychotics seen in female 
models (Pouzet et al., 2003, Albaugh et al., 2006, Minet Ringuet et al., 
2006a), and indeed weight loss has actually been reported in one study 
(Baptista et al., 1993).
Surprisingly, clozapine which has a similar receptor binding profile to 
olanzapine plus a comparable weight gain inducing propensity and 
metabolic modifying action in the clinic, has failed to induce weight gain 
in female rat models (Baptista et al., 1993, Albaugh et al., 2006, Cooper 
et al., 2008). On the contrary, weight gain has been reported in male 
rats (Albaugh et al., 2006, Sondhi et al., 2006).
Fewer studies have been performed using the mouse as a model. Kaur 
and Kulkarni (2002) reported weight gain in female mice treated with 
clozapine as did Zarate et al., (2004) though this latter finding was 
observed in male mice. In contrast, Cheng et al., (2005) described a 
weight loss in clozapine-treated male mice.
Moreover, Cope et al., (2005) and Coccurello et al., (2006-2008) 
described a weight increase in female mice treated with olanzapine, 
whilst Albaugh et al., (2006) was unable to show any changes versus 
olanzapine-treated controls.
It is therefore evident that findings in this field of investigation are quite 
heterogeneous and at times, contradictory probably due to a number of
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factors that appear to undermine their reproducibility. Hence, not only 
different species (rat or mouse) but also different strains within the 
same species have yielded different body weight outcomes. 
Furthermore, several research groups have highlighted the importance 
of gender difference, with female rodents being regarded as more 
inclined to gain weight than males in response to antipsychotic agents.
In addition, other factors that might potentially account for these 
discrepancies must be sought within the varieties of methodologies and 
protocols used by different laboratories. Such factors include disparity 
of dose, length of treatment and route of administration.
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A uthors SDecies/Strain Sex Drugs Route Duration Results
Baptista (1993) R/Wistar F/M CLO 0.5,1,2.5,5,10,20mg/kg IP 21 days =BW fern
|B W  male (10,20mg/kg)
Goudie (2002) RAVistar F OLA 4mg/kg (2Xday) IP 10 days fBW
Pouzet (2003) R/Wistar F/M OLA 5,20mg/kg (2Xday) OS 21 days fBW;FIfem =BW;F1 male
Aijona (2004) R/SD F OLA 1.2mg/kg OS 10 days |BW ;FI
Fell (2004) R/HL F OLA 0.5,l,4mg/kg IP 21 days TBW;FI;FD
C ooper(2005) R/H Wistar F OLA l,2,4mg/kg (2Xday) IP 20 days tBW;FI;FD
K.alinichev(2005) R/Wistar
Wistar-SD
F
F
OLA 5mg/kg (2Xday) 
OLA l,2,10mg/kg (2Xday) 
ARI 2,4,8mg/kg
OS 14 days 
7days
TBW;FI;FD 
|BW >in Winstar
Kalinichev(2006) R/SD F OLA 2mg/kg (2Xday) 
ZIP 2,6,10mg/kg (2Xday)
OS 7 days fBW
TBW
Albaugh(2006) R/SD-Wistar F/M OLA increasing dose from 
4 to 20mg/kg over time 
CLO increasing dose from 
4 to 8mg/kg over time 
CLO+OLA 8+4mg/kg
SA 33 days
12 days
13-24 * 
day
|BW ;FI fem;FD;L
=BW
=BW
Minet-Ringuet
(2006a)
R/SD M OLA 1 mg/kg 
ZIP lOmg/kg
SA 6 weeks =BW;FI fFD;L
Minet-Ringuet
(2006b)
R/SD M OLA 0.01,0.1,0.5,2mg/kg SA 6 weeks |BW ;FD
Patil (2006) R/SD F OLA l,2mg/kg IP 20 days tBW ;BP
C ooper(2008) R/Wistar 
R/H Wistar
F
F
CLO 6,12mg/kg (2Xday) 
CLO 1,4mg/kg (2Xday)
CLO 0.25,0.5mg/kg (2Xday)
IP 21 days 
20 days
12 days
JBW
iBW;=FI,I,L,GIu;
TFD,Adi
jB W
Evers (2010) R/Wistar F OLA 5mg/kg (2Xday) OS 14 days tBW;=LA;FI
K aur(2002) M/laca F CLO 2mg/kg,FLU lOmg/kg 
CLO+FLU
IP 21 days CLOtBW ;FI 
CLO+FLU reverse it
Zarate (2004) 
Cheng (2005)
M/AJ
M/C57BL/6J
M/Balb/c
M
M
M
CLO 2,4mg/kg 
CLO 2,4mg/kg
CLO 2,10mg/kg
IP
IP
18 days 
18 days
30 days
TBW(4mg/kg) 
t  BW(4mg/kg) 
|BW (10mg/kg) 
=BW (2mg/kg)
C ope(2005) M/CB57BL/6J F OLA 3,6mg/kg 
QUE 15,30mg/kg 
RIS 0.125,0.25mg/kg 
ZIP 7,10.5mg/kg
SA 4 weeks
|BW ;FI;FD
A lbaugh(2006) M/AJ
M/C57BL/6J
F
F
OLA increasing dose from 
4 to 8mg over time
SA 18 days =BW
Coccurello
(2006)
M/CD1 F OLA 0.75,1.5,3mg/kg 
OLA 3 mg/kg 
OLA 4,8mg/kg
OS
OP
36 days 
30 days 
28 days
t B W ;FI;FD;I,T ri(3 mg/kg)
=EE
tBW;FI
Coccurello
(2008)
M/CD1 F OLA 3,6mg/kg SA 50 days OLA3:tBW ;FI;FD 
Chol;Glu;Tri;I 
O LA6:tBW ;Glu;Tri 
i  FI
Table 3A CLO: Clozapine; OLA: Olanzapine; AR1: Aripiprazole; ZIP: Ziprasidone; FLU: fluoxetine; QUE: Quetiapine; IP: 
intraperitoneal; OS: oral gavage; SA: self-administration; OP: osmotic pump; BW: body weight; FD: fat deposition; FI: food intake; L: 
leptin; BP: blood pressure; I: insulin; Glu: glucose; Adi: adiponectin; Tri: triglycerides; Choi: cholesterol; LA: locomotor activity.
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3.1.1 Pharmacological approach to counteract APS-induced 
metabolic side effects
Along with the search for the reliable animal model of APS-induced 
weight gain and/or a drug-perturbed metabolism, a few clinical studies 
have been performed in order to test the possibility that patients could 
benefit from the introduction of adjunctive therapy with an anti-obesity 
medication. However, a lack of understanding of the mechanism 
underlying APS-induced weight gain complicates the development of a 
pharmacologic approach to the problem.
One of the drugs approved for the treatment of obesity is orlistat which 
inhibits enteric lipase to reduce fat absorption. Its absence of any CNS 
activity might render orlistat a suitable candidate in the above capacity 
as a treatment for APS-induced weight gain. In this context, there have 
been two case reports which showed firstly that a patient taking 
antipsychotic medications displayed a decrease in BMI from 36.3 kg/m2 
to 31.4 kg/m2 in 12 months of orlistat treatment and another who lost 3 
kg after 3 months (Anghelescu et al., 2000). Unfortunately, the use of 
this drug is restricted by unwanted gastrointestinal side effects, which 
dictate that orlistat therapy must proceed in combination with a low-fat 
diet.
Some clinical studies reported that the addition of metformin, the most 
prescribed oral hypoglycemic agent for the treatment of type 2 diabetes, 
to olanzapine therapy has been effective not only in improving insulin
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sensitivity but also in reducing weight gain (Baptista et al., 2007; Wu et 
al., 2008). Thus, metformin could be looked upon as a potential agent to 
be introduced in clinical practice for the management of antipsychotic- 
induced metabolic side effects.
3.1.2 Aim of the study
The experiments in this study were designed to search for a suitable 
mouse model since few investigations have been conducted using 
mice.
The experimental design was based on that of Cope et al., (2005). The 
same sex and animal strain (female C57BL/6J mice) and a chronic oral 
self-administration route were used. However, mixing the drug with 
honey as an oral delivery vehicle was found to be preferable to 
incorporating the drug in peanut butter pills, as shown in the habituation 
study previously conducted in the laboratory. This mode of 
administration proved to be much less invasive for the animals than 
either intraperitoneal injection or the oral route of administration 
(gavage). In addition to body weight changes, the rate of fat deposition 
was also monitored by weighing the intrabdominal, perirenal and 
periuterine white adipose tissue (post-mortem).
Furthermore, in this pilot study the ability of metformin to attenuate 
clozapine-induced weight gain was also tested.
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3.2 Results
3.2.1 Effect of olanzapine (10 mg/kg) on body weight and fat 
deposition
There was, as expected, a linear increase in body weight for both 
treatment groups (Fig 3.1a). Mice treated with olanzapine (10 mg/kg) 
exhibit some initial weight loss in the first three days of treatment. 
Moreover, there was not significant weight difference between the two 
groups for the first 16 days while a significant increase in body weight 
was seen after 17 days until the end of the treatment (P<0.05) 
compared with the placebo controls group.
In addition, weight gain was accompanied by a highly significant 
augmentation of fat deposition (P<0.01) (Fig 3.1b).
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Fig 3.1a Experiment 1. Effect of chronic oral administration of olanzapine (10 mg/kg) 
on mouse body weight over 28 days. n=12; values represent the means +/- SEM; (*P< 
0.05).
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Fig 3.1b Experiment 1. Effect of chronic oral administration of olanzapine (OLA) (10
mg/kg) on fat deposition (pooled fat pads) in mice. r?=12; values represent the means
+/-SEM; (**P<0.01).
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3.2.2 Effect of olanzapine (5 mg/kg and 15 mg/kg) on body weight 
and fat deposition
Mice were administered a lower dose of olanzapine (5 mg/kg), and also 
a higher dose (15 mg/kg) compared with the previous experiment. 
Evaluation of cumulative weight gain over days showed that there were 
no group differences over the 28 days of treatment.
Although no significant difference was attained, olanzapine at the dose 
of 5 mg/kg induced a consistent weight gain, with respect to time, 
compared to the placebo control group.
By the way of contrast, olanzapine at 15 mg/kg did not produce any 
significant trend towards weight loss over the period of the treatment 
(Fig 3.2a).
Contrary to the first dose tested of 10 mg/kg, no significant difference 
was seen in terms of enhanced deposition of white adipose tissue 
between groups (Fig 3.2b).
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Fig 3.2a Experiment 2. Effect of chronic oral administration of olanzapine (5 and 15 
mg/kg) on mouse body weight over 28 days. n=10; values represent the means ± 
SEM.
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Fig 3.2b Experiment 2. Effect of chronic oral administration of olanzapine (OLA) (5
and 15mg/kg) on fat deposition (pooled fat pads) in mice. n=10; values represent the
means ± SEM.
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3.2.3 Effect of clozapine (4 mg/kg and 8 mg/kg) on body weight and 
fat deposition
Oral administration of clozapine (4 mg/kg and 8 mg/kg) did not promote 
any extra weight gain compared with the placebo control group (Fig 
3.3a).
Both doses of clozapine increased white adipose tissue deposition 
compared to the placebo control group instead, although only the lower 
dose of 4 mg/kg attained significance (P<0.05), (Fig 3.3b).
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Fig 3.3a Experiment 3. Effect of chronic oral administration of clozapine (4 and 8 
mg/kg) on mouse body weight over 28 days. n=10; values represent the means ± 
SEM.
0) 0.5
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control clo 4mg/kg clo 8mg/kg
Fig 3.3b Experiment 3. Effect of chronic oral administration of clozapine (CLO) (4 and
8 mg/kg) on fat deposition (pooled fat pads) in mice. n=10; values represent the
means ± SEM; (*P<0.05).
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3.2.4 Effect of clozapine (15 mg/kg and 25 mg/kg) on body weight 
and fat deposition
Evaluation of cumulative weight gain over the 28 day treatment period 
showed that clozapine (15 mg/kg) significantly increased body weight 
compared to the placebo control group throughout the period of the 
treatment (P<0.01).
The higher dose (25 mg/kg), also significantly increased body weight on 
several intermittent treatment days, 3-7, 11-14 and 22, in comparison to 
the control group (Fig 3.4a).
Notably, in the first 7 days of treatment, the control group animals lost 
weight but there is no obviously identifiable causative explanation. 
However, clozapine treatment at doses of 15 mg/kg and 25 mg/kg did 
not enhance white fat deposition (Fig 3.4b).
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Fig 3.4a Experiment 4. Effect of chronic oral administration of clozapine (15 and 25 
mg/kg) on mouse body weight over 28 days. n=10; value represent the means ± SEM; 
(clozapine 25mg/kg vs. control: *P<0.05 **P<0.01; clozapine 15mg/kg vs. control: 
++P<0.01).
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Fig 3.4b Experiment 4. Effect of chronic oral administration of clozapine (CLO) (15
and 25 mg/kg) on fat deposition (pooled fat pads) in mice. n=10; values represent the
means ± SEM.
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3.2.5 Effect of clozapine (15 mg/kg), metformin (500 mg/kg) and 
clozapine (15 mg/kg) + metformin (500 mg/kg) on body weight and 
fat deposition
In experiment 5, clozapine at the dose of 15 mg/kg, which in experiment 
4 caused significant weight gain throughout the treatment, was 
administered again alone and in combination with metformin 500 mg/kg. 
The aim of this experiment was to evaluate whether metformin was 
capable of counteracting the increase in weight induced by clozapine.
Contrary to what was observed in the previous experiment, mice treated 
with clozapine (15 mg/kg) did not increase their body weight compared 
to the control group and generally, no difference was noted between 
any groups compared to control (Fig 3.5a). Notably, the control group 
weight gain was similar to that observed in experiment 4.
In accord with the results of experiment 4, clozapine (15 mg/kg) did not 
enhance fat deposition in a significant manner. Likewise, neither the 
treatment with metformin alone, nor a combination with clozapine, 
affected fat deposition (Fig 3.5b).
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Fig 3.5a Experiment 5. Effect of chronic oral administration of clozapine (15 mg/kg), 
metformin (500 mg/kg) and clozapine (15 mg/kg) + metformin (500 mg/kg) on mouse 
body weight over 28 days. r?=9; values represent the means ± SEM.
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Fig 3.5b Experiment 5. Effect of chronic oral administration of clozapine (CLO) (15 
mg/kg), metformin (MET) (500 mg/kg) and clozapine (15mg/kg) + metformin (500 
mg/kg) on fat deposition in mice. n=9; values represent the means ± SEM.
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3.2.6 Effect of clozapine (15 mg/kg and 25 mg/kg), and olanzapine 
(10 mg/kg and 12.5 mg/kg) on body weight and fat deposition
In previous experiments (1 and 3) it was observed that olanzapine (10 
mg/kg) and clozapine (15 mg/kg) induced a significant weight gain in 
female mice. However, when clozapine (15 mg/kg) had been tested for 
a second time alone and in combination with metformin, none of the 
groups showed significant weight differences compared to the control 
group and clozapine did not enhance body weight gain. Thus, it was 
considered essential to repeat the experiment administering clozapine 
and olanzapine at the doses previously capable of inducing significant 
weight gain. The dose of clozapine 25 mg/kg was also tested again. 
Furthermore, one additional dose of olanzapine was introduced i.e. 12.5 
mg/kg.
Unfortunately, none of the results achieved previously were reproduced 
in this experiment. All the groups of animals treated with the test 
compounds at any dose lost weight compared to the control group, and 
this weight loss achieved statistical significance (P< 0.05) on a few 
intermittent days for olanzapine 10 mg/kg (day 20, 25, 26) and 
clozapine 25 mg/kg (day 12,17, 19, 24), (Fig 3.6a).
In the earlier experiment 1, olanzapine (10 mg/kg) increased fat 
deposition in a highly significant manner, and clozapine (15 and 
25mg/kg) slightly increased it but without achieving statistical 
significance. In this repeated experiment however, neither of the 
antipsychotic compounds at any doses tested enhanced fat deposition
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and olanzapine at 10 mg/kg even yielded a slight reduction (P>0.05) 
(Fig 3.6b).
1 '♦ control clozapine 25mg/kg — olanzapine 10mg/kg
4 O olanzapine 12.5mg/kg x clozapine 15mg/kg
3O)
O) 2erf *“
U)
0
-1 days
Fig 3.6a Experiment 6. Effect of chronic oral administration of clozapine (15 and 25 
mg/kg) and olanzapine (10 and 12.5 mg/kg) on mouse body weight over 28 days. n - l \  
values represent the means ± SEM; (clozapine 25mg/kg vs. control: *P<0.05; 
olanzapine 10mg/kg vs. control: +P<0.05).
0.7
control ola 10mg/kg ola 12.5mg/kg clo 15mg/kg clo 25mg/kg
Fig 3.6b Experiment 6. Effect of chronic oral administration clozapine (CLO) (15 and
25 mg/kg) and olanzapine (OLA) (10 and 12.5 mg/kg) on fat deposition in mice. n=7;
values represent the means ± SEM.
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3.3 Discussion
The study shows that female C57BL/6J mice chronically treated with 
the antipsychotic drugs clozapine and olanzapine via the oral route, do 
not develop a significant repeatable increase in body weight nor 
reproducibly enhance the overall accumulation of white adipose tissue 
in the intrabdominal, perirenal and periuterine areas.
Thus, olanzapine (5,12.5 and 15 mg/kg) did not produce any significant 
weight gain or excessive fat deposition. While at a dose of 10 mg/kg it 
had no effect on body weight for the first 16 days of treatment, but 
subsequently increased body weight significantly, i.e. the difference in 
weight gain between the two groups being maintained from day 17 to 
day 28.
However, when the treatment was repeated under the same 
experimental conditions (using different animals), to validate the 
previous result, olanzapine failed to produce any significant weight gain 
throughout the length of the treatment.
Similarly, in the first attempt to reproduce an augmentation of fat 
deposition consistent with that observed in the clinic, olanzapine (10 
mg/kg) significantly enhanced fat accumulation (P<0.01) but this result 
was not observed when the experiment was repeated.
Furthermore, this pattern was also witnessed in mice chronically treated 
with clozapine. Hence, clozapine at the doses of 4 and 8 mg/kg did not 
generate any significant body weight gain compared to controls, while
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at a dose of 15 mg/kg it induced weight gain on all 28 days of treatment, 
and on several intermittent days at the dose of 25 mg/kg.
In an identical fashion to olanzapine described above, when the 
experiment was repeated, clozapine (15 and 25 mg/kg) seemed to 
produce weight loss relative to the steady weight gain of the control 
group when the experiment was repeated.
Consistent with the previous data however, clozapine at both of the 
higher doses of 15 and 25 mg/kg did not promote accumulation of 
visceral fat tissue.
On the other hand, clozapine at 4 mg/kg significantly enhances fat 
deposition without promoting weight gain, although the experiment was 
not duplicated. This pattern of observation is not novel and has been 
reported in other studies where clozapine and olanzapine induced fat 
deposition but no weight gain respectively in female rats (Cooper et al., 
2008) and male rats (Minet-Ringuet et al., 2006; Cooper et al., 2007). It 
might be suggested that the increase in adipose tissue following 
antipsychotic treatment may be somehow independent of weight gain 
and this requires further investigation to establish whether these drugs 
exert a direct effect on lipolysis and lipogenesis.
In the light of these findings, however, the contradictory results on body 
weight gain and fat deposition are not readily explicable given the fact 
that weight changes in mice in response to olanzapine and clozapine 
using the conditions and parameters in the current study do not 
represent a robustly reproducible animal model.
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On the basis of dose alone, rather than other factors (species, strain, 
sex, route of administration and treatment duration), these results are in 
disagreement with those of Zarate et al., (2004) who reported that 
clozapine (4 mg/kg) induced significant weight gain, and those of Cope 
(2005) and Coccurello et al., (2005-2008) where olanzapine at doses of 
3, 4, 6, 8 mg/kg significantly increase body weight. Such findings 
however, contrast with those of Albaugh et al., (2006) where olanzapine 
administered in increasing doses from 4 to 8 mg/kg did not affect body 
weight.
The wide range of doses of antipsychotics chosen in the current study, 
as well as those used by others in the literature, are intended to reflect 
doses employed in the clinic. The choice of the right antipsychotic drug 
and its optimal dose clinically normally requires a few weeks of 
monitoring and are matched to the individual patient.
To complicate matter further, the dosage of clozapine used in the clinic 
is in the range 150 and 450 mg/day and this is 15 times higher than that 
employed for olanzapine (Baldessarini et al., 2001). According to 
Albaugh et al., (2006) the correspondent dose-transformation to rodent 
is 40-50 mg/kg/day for clozapine, which would certainly produce a 
marked sedative effect potentially interfering not only with food intake 
but also energy expenditure.
Evidence of sedation was noted in the laboratory when clozapine was 
administered at a dose of 30 mg/kg and consequently treatment was 
suspended.
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Nevertheless, any veiled sedative effect of clozapine and olanzapine at 
the highest doses administered cannot be excluded in the present study 
because locomotor activity, food intake and energy expenditure were 
not measured.
Even though food intake is a simple variable to be measured in rodents, 
it is more difficult in small sized animals like individual mice due to the 
relatively small amount consumed and the degree of spillage. In 
addition, this would necessitate the animals being housed individually 
for the duration of the habituation plus treatment, and previous 
behavioral studies have proved that this leads to social isolation and 
distress, which may interfere with animal feeding behavior (Coccurello 
et al., 2006).
Ultimately, the range of doses currently used in the clinic and those 
employed in animal models, raise the question of dosage 
appropriateness in rodents that reflect those used for psychosis. 
Furthermore, the average half-lives of clozapine and olanzapine in 
humans are respectively 12 and 30 hours (Baldessarini et al., 2001), 
while they are only 1.5 hours for clozapine and 2.5 hours for olanzapine 
in rodents (Kapur et al., 2003). Hence, while human drug plasma levels 
are likely to be steady, in almost all the animal models that have been 
studied so far, the dosage regimen is no more than twice daily so 
plasma drug levels inevitably fluctuate compared to the clinical 
situation. This issue has been discussed by Kapur et al., (2003), who 
administered either by injection or by continuous infusion through
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osmotic mini-pump (MP), with several doses of drugs in both single and 
multiple dose regimens. Plasma concentrations and D2 receptor 
occupancy were measured simultaneously. The goal of Kapur’s study 
was to identify the appropriate doses capable of achieving plasma 
levels and receptor occupancy comparable to clinical occupancy levels 
and maintain them to a stable level. The rationale behind this study was 
that, not only such a short half-life of clozapine and olanzapine in 
rodents results in faster metabolism and elimination of these drugs, but 
that once or twice daily administration would not effectively mimic the 
drugs pharmacokinetics in humans.
Kapur et al., identified a range of doses administered several times a 
day by injection, were able to reach 70-80% D2 receptor occupancy but 
they did not maintain steady plasma levels. Conversely, the MPs 
delivery system did maintain stable plasma levels throughout the 24 
hours of infusion, accompanied by plasma level more representative of 
the conditions in the clinic.
The MP approach has several drawbacks however: firstly, the broad 
range of receptors that clozapine and olanzapine bind do not allow 
modeling of the dose-receptor occupancy relationship as a function of 
just D2 receptors so, in this respect, it represents an approximation of 
receptor binding.
Furthermore, injecting drugs several times a day does not represent a 
practical reality and although the MP system does lead to steady drug 
levels, it is invasive and labour intensive.
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Overall, the approach used by Kapur et al., although simplistic, it is 
nonetheless a further step towards the search for reliable criteria to 
match animal models to clinical treatments.
As in previous reports reviewed here, different methodologies account 
for different end results. In this context the age of the animals has a 
major influence. In the present study young animals (4-5 weeks old) 
were chosen in order to maximize any possibility of detecting 
distinguishable increase in body weight, which would have been less 
discemable in adult animals.
Additionally, 4 weeks was selected as appropriate treatment duration in 
order to increase the likelihood of an effect since the average length of 
previous studies conducted by others was 3 weeks.
Furthermore, whilst the influence that animal gender exerts is 
questionable since clinical observations report that weight gain is 
observed in male patients as it is in females (Meltzer et al., 2002; 
Ascher-Svanum et al., 2005), differences in species and strain (hence 
metabolism), might account for discrepancies in results. In this study 
C57BL/6J inbred mice were employed due to a lower degree of intrinsic 
variability distinctive of inbred strains compared to outbred strains. 
Nonetheless, outbred strains have also been employed by other 
authors but to a lesser extent. Additionally, inbred balb/c and AKR mice 
were utilized in a series of preliminary experiments but they were
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averse to Ingestion of the honey vehicle and as a consequence, the 
treatment was forced to be discontinued.
Taken together, several groups have reported models of APS-induced 
weight gain in rodents, but the findings of this investigation suggests 
that at least in mice, caution should be exercised in interpreting their 
reproducibility. An added perspective to this concept may be derived 
from the finding that the atypical antipsychotic ziprasidone, although it 
has little or no effect on human body weight (Allison et al., 1999) it does 
significantly promote weight gain in an animal model (Kalinichev et al., 
2006).
3.4 Conclusions
The main goals of this study were firstly, to produce a reliable and 
consistent mice model of clozapine and olanzapine-induced weight 
gain, and secondly, to test the ability of some agents to attenuate this 
weight increase. The drugs to be chosen for this purpose were either 
based on their application as anti-obesity agents or for their 
pharmacological action(s) on specific receptors to which olanzapine and 
clozapine bind.
Since the reproducibility of a mouse model of atypical antipsychotic- 
induced weight gain was not established by the study, it was not 
possible to perform any detailed experiments to probe agents as anti­
weight gain treatment against antipsychotics.
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Despite all the above-mentioned limitations, the search for a suitable 
animal model of weight gain should still be pursued, as well as further 
examination of metabolic dysfunction caused by these drugs and 
possible underlying mechanisms, which to date, are poorly understood.
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4. The effect of clozapine and olanzapine on 
adipogenesis: an in-vitro cell study
4.1 Introduction
The mechanism by which atypical antipsychotics, olanzapine and 
clozapine in particular, increase weight and cause metabolic 
disturbances, is yet to be elucidated. However, it is believed that the 
weight gain could, at least in part, be mediated by the action of these 
drugs on the hypothalamus: in the arcuate nucleus region of the 
hypothalamus there are two groups of neurons responsible for the 
feeding regulatory process, namely agouti-related neuropeptide Y 
(AgRP/NPY) and pro-opiomelanocortin/cocaine- and amphetamine- 
related transcript (POMC/CART). The former stimulates appetite while 
the latter suppress it (Schwartz et al., 2000).
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Several hormones regulate food intake, leptin and insulin play a major 
role in this control regulation, and their receptors have been found in 
AgRP/NPY and POMC/CART neurons. Leptin is secreted by adipocytes 
and its levels increase proportionally to body fat storage, thus, a 
decrease in fat storage results in lower circulating leptin and an 
increase in appetite (Meier and Gressner, 2004). Elevated plasma 
levels of leptin have also been found to be associated with antipsychotic 
treatment, however, patients under antipsychotic medications often do 
not experience a decrease in food appetite, suggesting a possible 
disruption of the mechanisms regulating the response to leptin in the 
hypothalamus (Jin et al., 2008).
As well as hormones, neurotransmitters such as serotonin, 
noradrenaline and histamine, participate in the regulation of eating 
behaviour and metabolism, their receptors being found in the 
hypothalamus. It has been observed that 5HTia agonists increase food 
intake while 5HT2C agonists decrease it (Clifton et al., 2000). The 
noradrenergic system also plays a role since the administration of ai - 
adrenoceptor agonists decreases food intake while the stimulation of 
a2 -adrenoceptor increases it (Ramos et al., 2005).
The role of histamine receptors in hypothalamic regulation of energy 
balance and food intake has also been studied (Yoshimatzu, 2006) and 
H1 antagonists have been shown to potently increase food 
consumption. Moreover, H1 receptor knockout mice appear to develop 
obesity (Deng et al., 2010). Olanzapine and clozapine have also been
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shown to activate H1 receptor-mediated AMP kinase (AMPK) in the 
hypothalamus, which results in an increase in food intake (Kim et al., 
2007).
4.1.1 Adipocyte differentiation
While several research groups have focused on the central, 
neurotransmitter-mediated effect of antipsychotic drugs to uncover the 
mechanisms by which these drugs cause weight gain and metabolic 
abnormalities, little has been investigated on their direct biological effect 
on adipogenesis in cultured pre-adipocytes and mature adipocytes.
The generation and increase of adipose tissue in the body is a 
consequence of an enlargement of mature adipocytes due to lipid 
accumulation (hypertrophy), and an augmentation of adipocyte 
numbers due to enhanced adipocyte differentiation from precursor cells 
(hyperplasia). In humans, the ability to generate new fat cells persists 
even at an adult stage (Gregoire et al., 1998), therefore, the goal of this 
study was to investigate whether the increase in body weight caused by 
clozapine and olanzapine is due to new formation of mature adipocyte 
from precursor cells.
Adipocytes derive from mesenchymal stem cells (MSCs). These 
progenitor cells have the ability to undergo differentiation into 
osteblasts, chondrocytes, adipocytes and myocytes.
Over the past decades, the establishment of several in-vitro models of 
adipogenesis have aided the advancement of knowledge of the cellular 
and molecular events involved in the differentiation of fibroblastic-like
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preadipocytes into mature adipocytes. This process occurs in several 
stages: first, the influence of hormones and growth factors (in a process 
that is yet poorly understood) drives the uncommitted cells to the 
specific adipogenic lineage. Pre-adipocytes then undergo a phase of 
growth arrest followed by mitotic clonal expansion, characterized by 
several more rounds of cell division, under the influence of adipogenic 
inducers, before terminal differentiation and formation of mature 
adipocytes (Gregoire et al., 1998; Lefterova and Lazar 2009). During 
this process cells change from a fibroblastic (stellate) to a spherical 
shape followed by accumulation of lipid droplets.
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Fig 4A Adipocyte differentiation process. (Adapted from Gregoire et al., 1998).
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Among the transcription factors involved in the differentiation and 
maturation process, peroxisome proliferator activated receptor gamma 
(PPARy) and CCAAT/enhancer binding proteins (C/EBPs) appear to 
play a key role (Cowherd et al., 1999).
PPARy is a member of the nuclear hormone receptor family. It is 
expressed in two isoforms PPARyl and PPARy2 with the latter being 
most abundant in fat tissue (Tontonoz et al., 1995). The expression of 
PPARy has been linked to morphological changes in fat cells, lipid 
accumulation and insulin sensitivity, which emphasizes its critical role in 
the process (Rosen et al., 2000). Several studies (Lefterova and Lazar 
2009) have demonstrated that PPARy is both necessary and sufficient 
to initiate adipocyte differentiation and that its deficiency is lethal in mice 
embryos. PPARy is also essential for mature adipocyte survival and its 
deletion leads to cell death (Imai et al., 2004).
Members of the C/EBP family have also been recognized as crucial 
transcription factors. In particular C/EBPa, C/EBPp and C/EBP6 are 
known to promote adipogenesis. C/EBPp and C/EBPS appear to be 
early markers of adipocyte differentiation, with C/EBPp even being 
capable of inducing differentiation without hormonal inducers (Yeh 
1995). Conversely, embryonic fibroblasts lacking both C/EBPp and 
C/EBP6 completely lose their adipogenic potential (Tanaka et al., 1997). 
C/EBPp and C/EBP6 are thought to promote adipogenesis through the 
induction of C/EBPa and PPARy expression (Yeh et al., 1995).
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C/EBPa, when activated, in turn induces the expression of several 
genes involved in terminal differentiation and lipid metabolism such as 
aP2, LPL, FAS and GLUT4 (Gregoire et al., 1998; Cowherd et al., 
1999).
In this study cultured mouse fibroblast-like cells 7-F2 are employed as a 
model to study adipogenesis. 7-F2 is a bone marrow-derived stromal 
cell line characterized by indefinite growth in-vitro and mesenchymal 
origin. These cells express osteoblastic markers but have the ability to 
differentiate into adipocytes, as demonstrated by mRNA over­
expression of adipocyte specific markers i.e. PPARy, adiponectin, aP2, 
adipsin, and confirmed by Oil Red O staining (Thompson et al., 1998; 
Muruganandan et al., 2010). Moreover, the conversion of 7-F2 cells into 
adipocytes is accompanied by a loss of the osteoblastic phenotype 
(Thompson et al., 1998).
4.1.2 Aim of the study
To determine whether clozapine and olanzapine have a direct influence 
on the formation of fat cells we investigated their effect in a fibroblast­
like cell line, 7-F2. In addition, we studied the effect of clozapine and 
olanzapine on the mRNA expression of several target genes involved in 
adipocyte differentiation and metabolism: PPARy, C/EBPp and 
lipoprotein lipase (LPL).
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4.2 Results
4.2.1 Effect of clozapine and olanzapine (1-100 pM) on the 
proliferation and viability of undifferentiated 7-F2 cells
The MTS assay and cell counting with haemocytometer were used to 
monitor the growth pattern of the cells under the influence of the test 
drugs, clozapine and olanzapine. A range of antipsychotic 
concentrations spanning 2 log units was first tested.
MTS assay
7-F2 cells were seeded into 96 well-plates (3,000 cells/well), then 
clozapine or olanzapine were added after 24 hours and cells allowed to 
proliferate for an additional 72 hours. The assay was carried out as 
described in paragraph 2.2.4. The optical density reading represents 
the concentration of formazan and its is proportional to the number of 
living cells.
Clozapine did not appear to affect cell proliferation at concentrations 
between 1 and 75 pM but it significantly (P< 0.05) reduced cells 
numbers at the highest concentration of 100 pM compared to control 
(Fig 4.1).
Olanzapine had no effect on proliferation (P> 0.05) at any of the 
concentration studied (Fig 4.2).
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Fig 4.1 The effect of clozapine (1-100 pM) on 7-F2 cell proliferation 
determined by MTS assay. The values represent the means ± SEM;* P< 0.05. 
n=3 from 3 independent experiments .
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Fig 4.2 The effect of olanzapine (1-100 pM) on 7-F2 cell proliferation 
determined by MTS assay. The values represent the means ± SEM; n=3 from 
3 independent experiments.
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Cell counting with haemocytometer
The rate of proliferation was also assessed by manual cell counting, 
and the trypan blue exclusion method allowed the determination of cell 
survival.
The cells were seeded in 6 well-plates, then clozapine or olanzapine 
were added after 24 hours and proliferation was allowed to proceed for 
72 hours. The assay was carried out as described in Chapter 2 
paragraph 2.2.5.
Clozapine significantly decreased (P<0.05) 7-F2 cell numbers at 
concentrations between 15 and 100 pM (Fig 4.3a).
Although statistical analysis did not detect any significant decrease in 
cell number, suggesting that olanzapine does not affect the rate of cell 
growth, the graphic data did show a trend towards a decrease in cell 
number compared to control, particularly between the concentrations of 
10 and 100 pM (Fig 4.4a). The high variability in the data may well have 
masked any possible significance that might have been detected in 
comparison with controls.
Statistical analysis also showed that the percentage of viable cells was 
not affected by clozapine or olanzapine at any concentration compared 
with controls (Fig 4.3b; 4.4b) which overall suggests that both drugs 
may slow down the rate of cell proliferation without causing cell death.
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Fig 4.3a The effect of clozapine (1-100 ^M ) on 7-F2 cell proliferation 
determined by manual counting after 72 hr of incubation. The values represent 
the means ± SEM; * P< 0.05. n=3 from 3 independent experiments.
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Fig 4.3b The effect of clozapine (1-100 pM) on % 7-F2 cell viability derived 
from the ratio (viable cells/total cell number) x 100 as determined by trypan 
blue exclusion. The values represent the means ± SEM. n=3 from 3 
independent experiments.
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Fig 4.4a The effect o f olanzapine (1-100 ^M ) on 7-F2 cell proliferation 
determined by manual counting after 72 hr of incubation. The values represent 
the means ± SEM. n=3 from 3 independent experiments.
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Fig 4.4b The effect of clozapine (1-100 pM) on % 7-F2 cell viability derived 
from the ratio (viable cells/total cell number) x 100 as determined by trypan 
blue exclusion. The values represent mean ± SEM. n=3 from 3 independent 
experiments.
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4.2.2 Effect of clozapine and olanzapine (1-10 pM) on the 
proliferation and viability of undifferentiated 7-F2 cells 
MTS assay
The effect of clozapine and olanzapine on cell growth was evaluated 
with respect to time. Hence, the cells were incubated for 3, 5 and 7 
days and the rate of proliferation was measured.
The effect of clozapine was both time and dose dependent beyond 3 
days. Thus, after 3 days of incubation, clozapine at all concentrations 
had no significant effect (P> 0.05) on cell proliferation compared to 
control.
In contrast, at day 5, clozapine at 3, 5 and 10pM significantly 
decreased cell proliferation, and after 7 days the rate of proliferation 
decreased at all concentrations compared to control (Fig 4.5).
The effect of olanzapine was also time and dose dependent. Thus, like 
clozapine, olanzapine did not affect cell growth at day 3 compared to 
control. However, after 5 days of incubation, only the highest 
concentration (10pM) inhibited cell proliferation but at day 7, olanzapine 
significantly reduced (P<0.05) cell proliferation at all doses compared to 
control (Fig 4.6).
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Fig 4.5 The effect o f clozapine (1-10 pM) on 7-F2 cell proliferation determined 
by MTS assay. The values represent the means ± SEM between 
corresponding durations (days) of incubation; (* P< 0.05) n= 10 from 2 
independent experiments.
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Fig 4.6 The effect o f olanzapine (1-10 pM) on 7-F2 cell proliferation 
determined by MTS assay. The values represent the means ± SEM between 
corresponding durations (days) o f incubation; (*P< 0.05) n=10 from 2 
independent experiments.
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4.2.3 Effect of clozapine and olanzapine (1-10 pM) on cell 
differentiation:
Adipogenesis assay
7-F2 cells can differentiate into mature adipocytes if cultured in the 
presence of the necessary mix of adipogenic inducers.
During the process of adipogenic differentiation 7-F2 cells adopt a 
rounded morphology and develop accumulations of lipid droplets in the 
cytoplasm which are visible by phase contrast light microscopy. These 
lipid droplets within the cytoplasm of 7-F2 cells were stained with the 
lipophilic dye, Oil Red O, before qualitative analysis by light microscopy. 
To achieve a quantitative measure of lipid droplet accumulation in 7-F2 
cells lipid-bound Oil Red O was extracted with alcohol and assayed by 
UV-Vis spectrophotometry where the absorbance at 490 nm is 
assumed to be directly proportional to the lipid concentration in the cells 
(Kuri-Harcuch, 1978), (Fig 4B).
Fig 4B Undifferentiated 7-F2 cells (left), and 7-F2 cells after 5 days of adipogenic 
differentiation (right).
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Previous methodology adopted by the laboratory was slightly modified 
due to initial difficulties in extracting the Oil Red O.
Despite the fact that the volume of Oil Red O used was the same in 
both cells treated with normal (full) media and cells treated with the 
adipogenic inducer media, the inability to remove it from the wells 
resulted in no difference (P> 0.05) detected between undifferentiated 
and differentiated cells in the colorimetric Oil Red O assay (Fig 4.7a).
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Fig 4.7a Induction of adipogenic differentiation in 7-F2 cells. The initial method 
developed for the Oil Red O assay did not distinguish between 
undifferentiated cells (treated with normal growth media) and differentiated 
cells (treated with normal media+adipogenic mix inducers).
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Fig 4.7b shows that by modifying the protocol (as described in 
paragraph 2.2.6), the colorimetric assay was able to show how the 
differentiation process was not initiated in cells cultured in normal (full) 
media (in absence of adipogenic inducers). Two days after the 
differentiation started, no difference (P> 0.05) was seen between the 
cells treated with normal media and the cells treated with adipogenic 
media. After 5 days however, there was a 2.5 fold difference (P< 0.05), 
and a > 2 fold increase at day 8 (P< 0.05).
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Fig 4.7b Induction of adipogenic differentiation in 7-F2 cells with adipogenic 
mix. The modified Oil Red O method afforded a distinction between 
undifferentiated and differentiated 7-F2 cells. The values represent the means 
± SEM between corresponding durations (days) of incubation (*P< 0.05).
7-F2 cells were first seeded in 12 well-plates (day -1), then, 24 hours 
later either clozapine or olanzapine were added (day 0), and
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differentiated over a period of 8 days. The rate of differentiation was 
evaluated at specific time-points at 2nd, 5th and 8th day.
Fig 4.8 and Fig 4.9 show that the differentiation process reached its 
peak at day 5, and declined by day 8. Moreover, both drugs decreased 
adipogenesis in a time and concentration dependent manner.
At day 2 both clozapine and olanzapine did not affect cell differentiation 
at any concentration compared to control (Fig 4.8). This could be 
explained by the previous observation that at day 2 Oil Red O uptake 
was comparable in control cells (treated with adipogenic media) (Fig 
4.7b).
However, after 5 days of culture in adipogenic media, clozapine at 5 
and 10 pM reduced adipocyte formation from precursor compared to 
control. After 8 days of culture, adipogenesis was significantly reduced 
at the 3, 5 and 10 p,M concentrations compared to control (P<0.05) (Fig 
4.8).
Olanzapine significantly reduced (P<0.05) cell differentiation (3, 5 and 
10 pM) after 5 days of treatment with adipogenic inducers, while after 8 
days, only the highest concentration (10 \M ) decreased adipogenesis 
in a significant manner (P<0.05) (Fig 4.9).
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Fig 4.8 Quantification o f adipogenesis using Oil Red O staining in clozapine- 
treated 7-F2 cells. The values represent the means ± SEM.*P< 0.05 denotes 
statistical significance between clozapine-treated cells and corresponding 
control cells at a given day of culture n=8 from 4 independent experiments.
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Fig 4.9 Quantification o f adipogenesis using Oil Red O staining in olanzapine- 
treated 7-F2 cells. The values represent the means ± SEM.*P< 0.05 denotes 
statistical significance between olanzapine-treated cells and corresponding 
control cells at a given day of culture n=8 from 4 independent experiments.
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Day 2 Day 5 Day 8
Fig 4C Effect of clozapine on the time-dependent differentiation of 7-F2 
cells into adipocytes when cultured in the presence of adipogenic inducers. 
Lipid droplets are stained using Oil Red O (top (first row)= vehicle control 
cells; second row= clozapine 1 (liM; third row= clozapine 3|xM; forth row= 
clozapine 5^iM; fifth row= clozapine 10^iM).
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Day 2 Day 5 Day 8
Fig 4D Effect of olanzapine on the time-dependent differentiation of 7-F2 
cells into adipocytes when cultured in the presence of adipogenic inducers. 
Lipid droplets are stained using Oil Red O (top (first row)= vehicle control 
cells; second row= olanzapine V M ; third row= olanzapine 3^iM; forth row= 
olanzapine 5nM; fifth row= olanzapine 10piM).
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4.2.4 Effect of clozapine and olanzapine (1-10 pM) on cell 
proliferation and viability during the differentiation of 7-F2 cells
Cell counting with haemocytometer
Cells were seeded in 6 well-plates, then, 24 hours later, clozapine or 
olanzapine (dissolved in adipogenic inducers media) were added for a 
period of 8 days.
Over the 8 day period the 7-F2 cells differentiate into adipocytes during 
which time changes in cell number and cell viability were evaluated.
Neither clozapine nor olanzapine affected cell growth at any of the 
incubation periods up to 8 days or any at concentration up to 10 pM 
compared to control although, as previously observed, this result was 
characterized by high variability (Fig 4.10a; 4.11a).
Moreover, both clozapine and olanzapine did not affect cell viability at 
any day and at any concentration (Fig 4.10b and 4.11b).
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Fig 4.10a The effect o f clozapine determined by manual cell counting. The 
values represent the means ± SEM between corresponding durations (days) 
of incubation. n=3 from 3 independent experiments.
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Fig 4.10b The effect of clozapine on % cell viability derived from the ratio 
(viable cells number/total cell number) x 100. The values represent mean ± 
SEM between corresponding durations (days) of incubation. n=3 from 3 
independent experiments.
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Fig 4.11a The effect of olanzapine determined by manual cell counting. The 
values represent the means ± SEM between corresponding durations (days) 
o f incubation. n=3 from 3 independent experiments.
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Fig 4.11b The effect of olanzapine on % cell viability derived from the ratio 
(viable cells number/total cell number) x 100. The values represent mean ± 
SEM between corresponding durations (days) of incubation, n- 3 from 3 
independent experiments.
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4.2.5 Effect of clozapine and olanzapine on gene expression of 
PPARy, C/EBPp and LPL in 7-F2 cells
7F2 cells were cultured for five days in the presence of adipogenic- 
inducer media, then total RNA was extracted, reverse transcribed in 
cDNA and analyzed using quantitative-Real Time PCR to evaluate the 
expression of three genes of interest: PPARy, C/EBPp and LPL. These 
genes were chosen since they are key markers of adipocyte 
differentiation.
Clozapine (5 pM) significantly increased C/EBPp expression by 4 fold 
(P< 0.05). The expression of PPARy was increased 3 fold although this 
increase was not significant (P> 0.05). Similarly, there was a slight 0.7 
fold increase in relative LPL mRNA expression although this was not 
significant (P> 0.05) (Fig 4.12).
A five day exposure of 7-F2 cells to olanzapine (3 pM) had little effect 
(P> 0.05) on the expression of mRNA encoding for PPARy, C/EBPp 
and LPL (Fig 4.13). Specifically, the relative expression of PPARy and 
C/EBPp increased 0.7 and 3 fold respectively, however, the variability 
between experimental replicates precluded the achievement of 
statistical significance. Notably, the mean relative expression of LPL 
was 30 % lower in 7-F2 cells treated with olanzapine; however this was 
not significant (P> 0.05).
126
Chapter 4
■  PPARgamma
clo 5 microM
c
.2 4 *-» m0
1 3 ■
f 2>
roa> 1
control
■C/EBPbeta6
5
4
3
2
1
0
control clo 5 microM
■  LPL
co
CO
E 2
c(0
a
!  1 
«Scc:
control clo 5 microM
Fig 4.12 Effect o f clozapine (CLO) (5 pM) on the relative mRNA expression of 
PPARy, C/EBPp and LPL in 7-F2 cells. The genes of interest are shown 
relative to that of housekeeper gene ARP as determined by qRT-PCR The 
values represent the mean ± SEM *P< 0.05. n =4 from 2 independent 
experiments.
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Fig 4.13 Effect of olanzapine (OLA) (3 pM) on the relative mRNA expression 
of PPARy, C/EBPp and LPL in 7-F2 cells. The genes of interest are shown 
relative to that of housekeeper gene ARP as determined by qRT-PCR The 
values represent the mean ± SEM. n=4 from 2 independent experiment.
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4.3 Discussion
To complement the in-vivo study described in chapter 3, a series of in- 
vitro experiments were designed to investigate the effect of APS drugs 
upon a cell line that may represent a suitable model for adipogenesis in- 
vivo.
7-F2 is a clonal cell line that originates from the bone marrow of p53-/- 
mice and it is characterized by indefinite growth in vitro and 
mesenchymal origin. However, despite expressing phenotypic 
osteoblastic markers, appropriate treatment with adipogenic inducers 
causes the loss of these markers and 7-F2 cells can convert to mature 
adipocytes (Thompson et al., 1998).
This preliminary study showed that both clozapine and olanzapine at 
concentrations up to 10 pM did not promote the differentiation of 
fibroblast-like cells 7-F2 into adipocytes compared to controls. 
Moreover, quantitative RT-PCR showed that mRNA expression of 
PPARy, C/EBPp and lipoprotein lipase (LPL) was not affected by 
olanzapine treatment while clozapine up-regulated gene expression of 
C/EBPp but not that of PPARy and LPL.
In this study clozapine and olanzapine were tested for the first time on 
7-F2 cells, therefore the initial aim was to evaluate their effect on the 
pattern of cell growth using an MTS assay and a manual cell counting 
technique (trypan blue exclusion). A wide range of concentrations was
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initially chosen and incubated with cells for 72 hours (1-100 ^M): MTS 
assay showed that clozapine (100 pM) significantly reduced cell viability 
while olanzapine did not significantly affect viability at any concentration 
(Fig 4.1; 4.2). Conversely, manual cell counting revealed that clozapine 
significantly decreased cell number at concentrations between 15 and 
100 pM while olanzapine at all concentrations (except 5 ^M) reduced 
cell number but without achieving statistical significance (Fig 4.3a; 
4.4a). Nonetheless, neither of the drugs seemed to affect cell viability 
by trypan blue (Fig 4.3b; 4.4b), suggesting that both clozapine and 
olanzapine may slow the rate of proliferation without affecting cell 
survival.
Subsequently, an MTS was employed to measure 7-F2 cells 
mitochondrial activity over an extended period of time in the presence of 
clozapine or olanzapine (1-10 jaM). This was used as an indicator of 
cellular proliferation in the presence of APS drugs. Both drugs, as 
previously observed by manual cell counting, did not affect the rate of 
proliferation after 3 days (72 hours), however, after 5 days, both drugs 
at several concentrations reduced proliferation and, after 7 days of 
treatment cell proliferation decreased at all concentration tested (1-10 
p,M) (Fig 4.5; 4.6), overall suggesting that prolonged treatment with 
clozapine and olanzapine, even at low doses, negatively affected cell 
survival.
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This study also aimed to provide an insight into a possible direct effect 
of these drugs in enhancing adipocyte differentiation: Fig 4C and 4D 
show the differentiation process at different stages up until the 
appearance of mature adipocytes with the characteristic lipid droplets 
stained in red by the lipophilic Oil Red O dye. The pattern of the 
differentiation appeared to be the same for control and drug-treated 
cells. Oil Red O staining of 2-day cultures revealed the virtual absence 
of lipid droplets which indicate that this is an early stage of the 
differentiation process. After 5 days culture, numerous lipid droplets 
were seen as an indicator of a mature adipocyte phenotype. A decrease 
in lipid droplets was however noted after 8 days of induction.
Contrary to what was hypothesized initially, that clozapine and 
olanzapine might directly promote the differentiation of fibroblast-like 
cells into adipocytes, the adipogenesis assay appeared to indicate that 
these drugs actually prevent their formation (Fig 4.8; 4.9). However, the 
qRT-PCR data, although limited in sample size, did not fully support 
these results i.e. olanzapine (3 \xNi) had no significant effect on the 
mRNA expression of PPARy, C/EBPp and LPL compared to controls 
(Fig 4.13). Similarly, the treatment with clozapine (5 \M ) had no 
significant effect on the mRNA expression of PPARy and LPL, but up- 
regulated C/EBPp expression by 4 fold (Fig 4.12). The drug treatment 
conditions used in these qRT-PCR studies equaled the lowest 
respective drug concentration that produced a significant increase in
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lipid accumulation as determined by quantitative Oil-Red O assay (Fig 
4.8, Fig 4.9) and the duration of culture (i.e. 5 days) that produced the 
peak of lipid droplet accumulation in control cell cultures treated with 
adipogenic factors.
The low number of experimental replicates employed in the qRT-PCR
and the high variability between the samples limited the statistical 
power of these experiments, however, further studies may show the 
subtle trend in gene expression to be significant.
It is not clear however, whether reduced adipocyte differentiation 
reflects a direct effect on adipocyte formation or if it is a consequence of 
the effect of clozapine and olanzapine on the inhibition of cell 
proliferation and survival. Thus, a cell counting was run parallel to the 
adipogenesis assays to evaluate cell proliferation and viability during 
the differentiation process. Both clozapine and olanzapine did not affect 
cell number or survival (Fig 4.10a-b; 4.11a-b).
Few studies to date, have investigated the potential influence of these 
drugs on recruitment and differentiation of adipocyte precursor cells and 
findings are conflicting: clozapine enhanced the differentiation of human 
primary pre-adipocytes (Hemmrich et al., 2006) and that of 3T3-L1 pre­
adipocytes (Yang et al., 2009). Similarly, olanzapine was also found to 
promote adipocyte formation from 3T3-L1 pre-adipocytes (Yang et al., 
2007). By contrast, and in accordance with the study presented here,
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Hauner et al., (2003), did not find clozapine to promote adipocyte 
differentiation in primary pre-adipocytes.
However, the idea that clozapine and olanzapine may directly perturb 
lipid metabolism has been the object of a number of investigations.
It was shown that clozapine and olanzapine (but the latter to a less 
extent) have a direct effect on cell metabolism through their action on 
peripheral tissues, and up-regulation of cholesterol and fatty acid 
biosynthesis (mediated by sterol regulatory element binding proteins 
SREBPs), was reported in glioma cells and hepatocytes (Ferno et al., 
2005- 2006-2009; Reader et al., 2006). Moreover, an increase in lipid 
accumulation accompanied by a decrease in lipolytic activity in 
adipocytes has also been described (Minet-Ringuet et al., 2006; Vestri 
et al., 2007).
Although the results reported in this study suggest that clozapine and 
olanzapine do not promote in-vitro new cell recruitment and formation of 
fat cells, this might indirectly support some of the findings reported by 
others which suggest that these drugs may directly disturb lipogenesis 
and lipolysis in adipocytes (Minet-Ringuet et al., 2006; Vestri et al., 
2007). Therefore, body weight gain and adiposity might be, at least in 
part, caused by a direct peripheral effect of clozapine and olanzapine 
on cell metabolism, possibly promoting accumulation of lipids and 
thereby causing adipocyte enlargement (hypertrophy) rather than tissue 
remodelling and increase in de- novo adipocyte formation.
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An additional consideration to take into account is that bone marrow- 
derived mesenchymal cells might not be the most appropriate cell 
model for studying adipogenesis. A recent study comparing the human 
phenotype of MSCs derived from adipose tissue (AMSCs) and bone 
marrow (BMSCs) showed that both share a similar immunophenotypic 
profile and, based on morphological changes (Oil Red O staining), both 
display positive adipocyte differentiation capabilities, but with AMSCs 
enhancing differentiation 7 fold more than BMSCs. However, no 
difference was seen between AMSCs and BMSCs in terms of mRNA 
expression of marker genes involved in adipogenesis and lipid 
metabolism (Pachon-Pena et al., 2010).
134
Chapter 4
4.4 Bibliography
Clifton P G, Lee M D, Dourish C T. Similarities of the action of R06O- 
0175, a 5HT2C receptor agonist and D-fenfluramine on feeding 
patterns in the rat. Psychopharmacol 2000; 152(3): 256-67.
Cowherd R M, Lyle R E, McGehee R E. Molecular regulation of 
adipocyte differentiation. Cell & Develop Biol 1999; 10: 3-10.
Deng C, Weston-Green K, Huang X F. The role of histaminergic H1 
and H3 receptors in food intake: a mechanism for atypical 
antipsychotic-induced weight gain? Prog Neuropharmacol Biol 
Psychiatry 2010; 34:1-4.
Ferno J, Reader M B, Vik-Mo A O, Skrede S, Glambek M, Tronstad 
K J, Breilid H, Lovlie R, Berge R K, Stansberg C, Steen V M. 
Antipsychotic drugs activate SREBP-regulated expression of lipid 
biosynthetic genes in cultured human glioma cells: a novel 
mechanism of action? Pharmacogen J 2005; 5: 298-304.
Femo J, Skrede S, Vik-Mo AO, Hivik B, Steen V M. Drug-induced 
activation of SREBP-controlled lipogenic gene expression in CNS- 
related cell lines: Marked differences between various antipsychotic 
drugs. BMC Neurosc 2006; 7: 69.
Ferno J, Vik-Mo A O, Jassim G, H£vik B, Berge K, Skrede S, 
Gudbrandsen O A, Waage J, Lunder N, Mork S, Berge R K, 
Jorgensen H A, Steen V M. Acute clozapine exposure in vivo 
induces lipid accumulation and marked sequential changes in the 
expression of SREBP, PPAR, and LXR target genes in rat liver. 
Psychopharmacol 2009; 203: 73-84.
Gregoire F M, Smas C N, Sul H S. Understanding adipocyte 
differentiation. Psycholog Review 1998; 78(3): 783-809.
135
Chapter 4
Hauner H, Rohrig K, Hebebrand J, Skurk T. No evidence for a direct 
effect of clozapine on fat cell formation and production of leptin and 
other fat cell-derived factors. Mol Psychiatry 2003; 8:258-9.
Hemmrich K, Gummersbach C, Pallua N, Luckhaus C, Fehsel K. 
Clozapine enhances differentiation of adipocyte progenitor cells. Mol 
Psychiatry 2006; 11:980-3.
Imai T, Takakuwa R, Marchand S, Dentz S, Bornert J M, Messadeq 
N, Wendling O, Mark M, Desvergne B, Wahli W, Chambon P, 
Metzger D. Peroxisome proliferator-activated receptor gamma is 
required in mature white and brown adipocytes for their survival in 
the mouse. Proc Natl Acad Sci USA 2004; 101: 4543-7.
Jin H, Meyer J M, Mudaliar S, Jeste D V. Impact of atypical 
antipsychotic therapy on leptin, ghrelin and adiponectin. 
Schizophrenia Research 2008; 100(1-3): 70-85.
Kim S F, Huang A, Snowman A M, Teuscher C, Snyder S H. 
Antipsychotic drug-induced weight gain mediated by histamine H1 
receptor-linked activation of hypothalamic AMP-kinase. Proc Natl 
Acad Sci USA 2007; 104(9): 3456-59.
Kuri-Harcuch W, Green H. Adipose conversion of3T3 
cellsdepends'ona serum factor. Proc. Nati. Acad. Set. USA 1978; 75 
(12): 6107-09.
Lefterova M I, Lazar M A. New developments in adipogenesis. 
Trends in Endocrinology and Metabolism 2009; 20(3): 107-14.
Meier U, Gressner A M. Endocrine regulation of energy metabolism: 
review of pathobiochemical and clinical chemical aspect of leptin, 
ghrelin, adiponectin and resistin. Clin Chem 2004; 50(9): 1511-25.
136
Chapter 4
Minet-Ringuet J, Even P C, Valet P, Carpen6 C, Visentin V, Prevot 
D, Daviaud D, Quignard-Boulange A, Tom6 D, de Beaurepaire R. 
Alteration of lipid metabolism and gene expression in rat adipocytes 
during chronic olanzapine treatment. Mol Psychiatry 2007; 12: 562- 
71.
Muruganandan S, Roman A A, Sinai C J. Role of 
Chemerin/CMKLRI in adipogenesis and osteoblastogenesis of bone 
marrow stam cells. JBMR 2010; 25(2): 225-34.
Pachon-Pena G, Yu G, Tucker A, Wu X, Vendrell J, Bunnell BA, 
Gimble J M. Stromal cells from adipose tissue and bone marrow of 
age matched female donors display distinct immunophenotypic 
profiles. J Cell Physiology 2010; Sept 20.
Ramos E J, Meguid M M, Campos A C, Coelho J C. Neuropeptide 
Y, alpha-Melanocyte-stimulating hormone, and monoamines in 
food intake regulation. Nutrition 2005; 21:269-79.
Reader M B, Femo J, Vik-Mo A O, Steen V M. SREBP activation by 
antipsychotic- and antidepressant-drugs in cultured human liver 
cells: Relevance for metabolic side-effects? Mol & Cell Biochem 
2006; 289: 167-73.
Reinolds G P, Kirk S L. Metabolic side effects of antipsychotic drug 
treatment-pharmacological mechanism. Pharmacol and Therap 
2010; 125:169-79.
Rosen E D, Walkey C J, Puigserver P, Spiegelman B M. 
Transcriptional regulation of adipogenesis. Genes & Dev 2000; 14: 
1293-1307.
Schwartz M W, Woods S C, Porte D Jr, Seeley R J, Baskin D G. 
Central nervous system control of food intake. Nature 2000; 
404:2195-2200.
137
Chapter 4
Tanaka T, Yoshida N, Kishimoto T, Akira S. Defective adipocyte 
differentiation in mice lacking the C/EBPp and/or C/EBP6 gene. 
EMBO J 1997; 16:7432-43.
Thompson D L, Lum K D, Nygaard S C, Kuestner R E, Kelly K A, 
Gimble J M, Moore E E. The derivation and characterization of 
stromal cell lines from the bone marrow of p53-/- mice: new insights 
into osteoblast and adypocite differentiation. J Bone Min Res 1998; 
13(2): 195-204.
Tontonoz P, Hu E, Devine J, Beale E G, Spiegelman B M. PPARy2 
regulates adipocyte expression of the phosphoenolpyruvate 
carboxykinase gene. Mol Cell Biol 1995; 15: 351-7.
Vestri H S, Maianu L, Moellering D R, Garvey W T. Atypical 
antipsychotic drugs directly impair insulin action in adipocytes: 
effects on glucose transport, lipogenesis, and antilipolysis. 2007; 
Neuropsychopharmacol 2007; 32: 765-72.
Yang Z, Yin J Y, Gong Z C, Huang Q, Chen H, Zhang W, Zhou H H, 
Liu Z Q. Evidence for an effect of clozapine on the regulation of fat­
cell derived factors. Clin Chi Acta 2009; 408: 98-104.
Yang L H, Chen T M, Yu S T, Chen Y H. Olanzapine induces 
SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol 
Research 2007; 56: 202-08.
Yeh W C, Cao Z, Classon M, McKnight S L. Cascade regulation of 
terminal adipocyte differentiation by three members of the C/EBP 
family of leucin zipper protein. Genes & Dev 1995; 15:168-81.
Yoshimatsu H. The neuronal histamine H1 and pro- 
opiomelanocortin-melanocortin 4 receptors: independent regulation 
of food intake and energy expenditure. Peptides 2006; 27:326-32.
138
Chapter 5
Chapter 5
The effect of clozapine on 
adipogenesis: an ex-vivo study
139
Chapter 5
5. The effect of clozapine on adipogenesis: an ex- 
vivo study
5.1 Introduction
In the previous chapter the effect of clozapine and olanzapine in 
influencing adipogenesis in cultured bone marrow-derived fibroblast-like 
cells was described. In this chapter we aimed to investigate clozapine 
ex-vivo effect on bone marrow cells obtained from the C57BL/6J mouse 
strain that was utilised in body weight gain experiments.
Since the generation of marrow fat is considered to be identical to 
adipogenesis in other tissues (Rosen et al., 2009), it is believed that the 
process follows the same highly regulated pathway. Under genetic, 
hormonal and dietary influence, bone marrow mesenchymal stem cells 
(MSCs) undergo a program of differentiation events under the overall 
control of transcription factors such as peroxisome proliferator activated
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receptor gamma (PPARy) and CCAAT/enhancer binding proteins 
(C/EBPs). PPARy and C/EBPs assume the role of master regulators by 
initiating a cascade of key factors involved in the various stages of the 
adipogenic differentiation.
Moreover, bone marrow MSCs have the potential to differentiate not 
only into adipocytes but also in osteoblasts, chondrocytes and 
myoblasts depending upon a complex interaction of extracellular 
mediators activating lineage-specific transcription factors which in turn 
drive the differentiation program towards a specific lineage (Takada et 
al., 2007) (Fig 5A).
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Fig 5A Differentiation potential o f bone marrow MSCs. (From Takada 2007).
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Interestingly, a certain degree of plasticity has been demonstrated 
between osteoblasts and adipocytes with a reciprocal relationship that 
enables the interconversion between these two lineages (Fig 5B).
For example, when cultured under appropriated in-vitro conditions in- 
vitro single MSCs were shown to be capable of differentiating into 
adipocytes, then later dedifferentiating and adopting an osteoblast 
phenotype. Similarly, mature osteoblasts are capable of differentiating 
to adipocytes, as well as the reverse whereby mature adipocytes 
dedifferentiate and become osteoblasts (Kassem et al., 2008).
When PPARy is expressed in osteoblasts it is able to suppress the 
osteoblast phenotype and redirect the differentiation towards the 
adipogenic pathway: this occurs by inducing the expression of the 
genes associated with the adipocyte phenotype such as lipoprotein 
lipase (LPL) and adipocyte lipid-binding protein aP2 (Lecka-Czernik et 
al., 1999).
LPL is a key enzyme involved in lipid transport, metabolism and 
storage, responsible for the hydrolysis of circulating triglycerides into 
free fatty acid and monoglycerides (Wang and Eckel 2009). It is also an 
important marker of adipocyte differentiation since its mRNA expression 
increases in parallel with cellular lipid accumulation (Bjorntorp et al., 
1978).
aP2 is part of a family of intracellular proteins capable of binding 
lipophilic ligands such as fatty acids (Benlohr et al., 1997). Although it is 
expressed in several tissues, is most abundant in adipose tissue
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(MacDougald and Lane 1995), and it is known to act as carrier to 
facilitate intracellular-lipid traffic forming a complex with long-chain fatty 
acids (Coe et al., 1999). It also represents an important marker of 
terminal adipocyte differentiation (Tontonoz et al., 1994).
5.1.1 Aim of the study
It was observed earlier in this thesis (chapter 3) that clozapine at the 
doses of 15 and 25 mg/kg induced a significant weight gain in female 
mice compared to the controls (Fig 3.4a). The dose of 15 mg/kg in 
particular promoted body weight gain through the duration of drug 
treatment.
Following this observation, the animals employed in the experiment 
were killed under terminal gaseous anaesthesia and the bone marrow 
from femur bones was collected and subjected to RNA extraction and 
qRT-PCR to evaluate the expression of four genes of interest. These 
genes were namely PPARy, aP2 and LPL, because of their role in 
adipocyte differentiation and lipid metabolism, and osteomodulin 
(OMD), a protein belonging to the leucine rich repeat protein family of 
proteoglycans; the over-expression of which is a reliable marker of 
increased osteoblast differentiation and mineralisation (Rehn 2008).
The aim of this study was to establish using qRT-PCR, whether 
clozapine, administered to C57BL/6J mice at a dose of 15 mg/kg could 
direct the differentiation of BMSCs towards the adipogenic pathway. 
Furthermore, we sought to investigate the effect of clozapine (15 mg/kg)
143
Chapter 5
on the expression of an osteoblastic marker gene (OMD), which may 
reveal whether the interconversion between adipocytes and osteoblasts 
can occur not only in vitro but also in vivo (Fig 5B).
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Fig 5B Differentiation and interconversion of bone marrow mesenchymal stem 
cells (BMSC) into adipocytes and osteoblasts.
This data may provide some evidence that clozapine (and possibly 
olanzapine) have a weight increasing effect mediated at the cellular 
level in addition to other possible central mechanisms.
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5.2 Results
5.2.1 Effect of clozapine (15 mg/kg) on gene expression of PPARy, 
LPL, aP2 and OMD in the bone marrow of C57BL/6J mice
Clozapine orally administered for 28 days at a dose of 15 mg/kg 
resulted in a significant up-regulation of mRNA encoding PPARy (P< 
0.05) and aP2 (P< 0.05) compared to controls (Fig 5.1 and 5.2). 
Conversely, LPL expression was not affected by clozapine 
administration (Fig 5.2).
In addition, clozapine treatment also produced a significant (P<0.01) 0.3 
fold down-regulation of the expression of OMD as shown in Fig 5.2.
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Fig 5.1 Effect of clozapine on mRNA expression o f PPARy in bone marrow as 
determined by qRT-PCR. The values represent the mean ± SEM *P< 0.05; 
n=10(10 animals/group).
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Fig 5.2 Effect of clozapine on mRNA expression of aP2, LPL and OMD in 
bone marrow as determined by qRT-PCR. The values represent the mean ± 
SEM. *P< 0.05; ** P<0.01; n=10 (10 animals/group).
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5.3 Discussion
The experiments described in this chapter were designed to determine 
whether the in-vivo mouse model that was described in chapter 3 
displayed any change in the levels of genetic markers of adipogenesis. 
By extracting bone marrow from clozapine-treated mice it was possible 
to determine by qRT-PCR whether the expression of marker genes 
were altered by clozapine treatment in comparison to control (vehicle- 
treated mice).
This study shows that in female C57BL/6J mice, chronic treatment with 
clozapine (15 mg/kg) for 28 days may stimulated bone marrow 
adipogenesis by increasing the expression of PPARy and aP2. PPARy 
and aP2 have been both implicated in the process of adipogenesis: 
PPARy initiates the cascade of events leading to the differentiation of 
precursor cells into adipocytes, and along with high levels of expression 
of PPARy, aP2 was also found to be up-regulated. This is not surprising 
as high levels of aP2 are linked to the development and maturation of 
the adipogenic phenotype (Tontonoz et al., 1994).
The finding that levels of LPL were not enhanced by treatment with 
clozapine was unexpected. In this matter, the direct contribution of LPL 
to lipid storage has been questioned by others. Weinstock et al. showed 
that in crossbred mice, despite the availability of fatty acids for 
adipocyte storage being dependent on the activity of LPL, when its 
expression is suppressed, there is little effect on the adipose tissue 
mass. This appeared to be due to a compensatory increase in de-novo
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endogenous synthesis of fatty acids (Weinstock et al., 1997). However, 
it was later shown that reducing LPL expression through siRNA 
knockdown, caused a reduction in intracellular lipid levels of 80% 
indicating that LPL is necessary for lipid uptake and storage (Gonzales 
and Orlando, 2007).
In this study we observed a highly significant reduction of the levels of 
OMD mRNA. This may indicate a decrease in the differentiation of bone 
marrow cells into osteoblasts, thus suggesting that the observed in-vitro 
reciprocal relationship between osteoblasts and adipocytes (Kassem et 
al., 2008) may also occur in-vivo in clozapine-treated mice.
Despite the cellular heterogeneity of the bone marrow samples 
employed here was a limitation of the study, an up-regulation of PPARy 
and aP2 mRNA levels, and a down-regulation of OMD mRNA levels 
seem to indicate that there are higher levels of bone marrow adiposity 
in animals chronically treated with clozapine compared to non-treated 
controls. As is the case with all qPCR quantification of mRNA levels it is 
desirable to follow-up these studies with experiments looking at relative 
protein levels.
Despite the function of marrow fat being largely unknown thus far, the 
generation of adipocytes from bone marrow MSCs (BMSCs) follows the 
same pathway of adipocyte formation from adipose MSCs (AMSCs) 
(Rosen et al., 2009; Pachon-Pena et al., 2010). In a recent study it was 
shown that histochemical assays suggested that AMSCs display a
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greater lipid accumulation potential than BMSCs. However, during 
adipogenesis, mRNA levels for PPARy, C/EBPa, adiponectin, leptin, 
LPL and aP2 were over-expressed in both AMSCs and BMSCs without 
any significant difference between them (Pachon-Pena et al., 2010).
It must be bome in mind that this is a preliminary investigation and 
further studies employing primary adipocyte culture should be 
undertaken. Moreover, other parameters such as adipocyte size, 
lipogenic and lipolytic activity should be investigated. Such an approach 
would provide additional evidence as to whether clozapine or 
olanzapine can directly affect adipogenesis and lipogenesis in an in- 
vivo model with relevance to the clinical situation.
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6.1 General discussion and conclusions
The development and introduction to clinical practice of second- 
generation antipsychotic drugs (“atypical”) represented a major 
breakthrough in the treatment of psychosis (Sheen, 1999). These 
agents improved the life of millions of patients with schizophrenia by 
substantially diminishing the disabling extrapyramidal side effects that 
had negatively impacted the lives of patients previously treated with the 
older antipsychotics.
In the past decade however, it has been recognized that atypical 
antipsychotic therapy may be associated with disturbing metabolic 
derangements (ANison et al., 1999; Newcomer, 2004; Lambert et al., 
2005). Body weight gain, adiposity, glucose dysregulation, insulin 
resistance and dyslipidemia, which are strongly associated with the 
onset of obesity, type 2 diabetes and cardiovascular diseases, are 
raising great concern among clinicians. The biological mechanisms
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underlying atypical antipsychotic-induced side effects remain largely 
unknown and therefore the development of preclinical animal models is 
essential for translational research.
In this study clozapine and olanzapine were investigated because of 
their well-established propensity to induce metabolic alterations 
compared to other atypical drugs such as risperidone and ziprasidone 
(Allison et al., 1999). Body weight gain and adiposity were chosen as 
parameters of interest because they represent the most perceptible 
metabolic side effects of these medications and as such, they are the 
source of major distress for patients, often leading to inadequate 
adherence to treatment (i.e. poor patient compliance), discontinuation 
and a consequent relapse of psychotic symptoms (Fontaine et al., 
2001).
The primary aim of the study was to mimic the degree of weight gain 
and adiposity seen in the clinic using female C57BL/6J mice. However, 
when significant weight gain in clozapine or olanzapine-treated animal 
groups was observed, these findings were not replicated in subsequent 
experiments. Thus, the development of a consistent and robust model 
was obstructed by variability and inconsistency of the experimental 
results. As shown in a number of previous studies, human weight gain 
and fat deposition has proved to be extremely challenging to model in 
rodents. In this context some studies have presented evidence of 
weight increase, some of weight loss and others have reported no
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difference (see Chapter 3, table 3A). Moreover, numerous rodent 
models appear to support the belief that weight gain is a more 
prominent feature in females rather than in males, although this does 
not truly reflect the clinical situation (Meltzer et al., 2002; Ascher- 
Svanum et al., 2005).
Doses and frequency of drug administration in these studies also 
represent another issue that might undermine the reliability of the final 
experimental outcomes. Clozapine and olanzapine have short half-lives 
in rodents (Kapur et al., 2003) which in turn give rise to faster drug 
elimination from the organism impeding sustained steady plasma levels 
to reduce the likelihood of observing weight increase (Kapur et al., 
2003).
Overall, the mixed success accomplished thus far in modeling weight 
gain and adiposity in rodents directly question the predictive validity of 
these models so much that it is suggested that rodents, and rats in 
particular, do not represent an optimal species to mimic the atypical 
antipsychotic-induced body weight gain and fat deposition seen in the 
clinic. Nevertheless, the search for a suitable animal model that reflects 
the range of metabolic alterations seen in patients treated with atypical 
antipsychotic medications is still a necessary step towards uncovering 
the mechanisms responsible for these major side effects, and 
ultimately, to drive the search towards a possible adjunctive treatment 
strategy to counteract them.
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The current in-vitro studies (chapter 4) indicate that clozapine and 
olanzapine do not promote adipogenesis based on the morphological 
assays in 7-F2 cells. This might lead to hypothesis that both drugs do 
not exert their metabolic effects through a direct action on adipocytes 
but rather that they increase body weight via central pathways. 
However, the ex-vivo investigation of bone marrow extracts from 
clozapine-treated mice showed that clozapine up-regulates mRNA 
expression of PPARy and aP2 which are well recognized markers of 
adipocyte differentiation and lipid formation. The limited nature of these 
observations using qRT-PCR only necessitate further investigation on 
lipolytic/lipogenic drug activity employing additional correlative 
methodologies.
As previously suggested, bone marrow-derived mesenchymal stem 
cells (BMSCs) may not be the optimal cell model to study adipogenesis 
and adipocyte metabolism (see Chapter 4), therefore, testing the 
adipogenic potential of these agents in a more established cell model of 
pre-adipocites such as 3T3-L1 cells and/or primary adipose tissue- 
derived mesenchymal stem cells (AMSCs) may provide a better 
understanding of whether these drugs can, at least in part, directly 
modify stem cell differentiation and affect adipocyte formation.
Additional studies are also needed to corroborate any possible direct 
effects at the mRNA transcriptional level of target genes driving the first 
stages of adipocyte formation. These include PPARy and C/EBPs, and
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genes involved in terminal differentiation and maturation such as aP2, 
LPL, FAS, GLUT4, and leptin (Cowherd et al., 1999).
Finally, previous reports have demonstrated that both clozapine and 
olanzapine are capable of activating lipogenesis and, in parallel, 
inhibiting lipolysis (Minet-Ringuet et al., 2006; Vestri et al., 2007). It 
would therefore be valuable to further investigate and establish in 
cultured adipocyte cell line and primary adipocytes, whether lipid 
accumulation and reduced lipolysis might conceivably be the 
preferential pathways by which clozapine and olanzapine directly alter 
adipocyte biology peripherally.
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